{"id":319846,"date":"2025-07-22T16:00:21","date_gmt":"2025-07-22T16:00:21","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/lly-stock-forecast-2\/"},"modified":"2025-07-22T16:00:21","modified_gmt":"2025-07-22T16:00:21","slug":"lly-stock-forecast","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/","title":{"rendered":"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?"},"content":{"rendered":"
<\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":308120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[39,45,44],"class_list":["post-319846","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-platform","tag-stock","tag-strategy"],"acf":{"h1":"Pocket Option LLY Hisse Senedi Tahmini","h1_source":{"label":"H1","type":"text","formatted_value":"Pocket Option LLY Hisse Senedi Tahmini"},"description":"Benzersiz lly hisse senedi tahmin analizi, \u00f6l\u00e7\u00fclebilir yapay zeka, blok zinciri ve makine \u00f6\u011frenimi yenilikleri arac\u0131l\u0131\u011f\u0131yla. Bu teknolojiler 2025 y\u0131l\u0131na kadar %15-25 de\u011ferleme primleri sunmadan \u00f6nce Pocket Option'\u0131n veri odakl\u0131 yat\u0131r\u0131m stratejilerine eri\u015fin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Benzersiz lly hisse senedi tahmin analizi, \u00f6l\u00e7\u00fclebilir yapay zeka, blok zinciri ve makine \u00f6\u011frenimi yenilikleri arac\u0131l\u0131\u011f\u0131yla. Bu teknolojiler 2025 y\u0131l\u0131na kadar %15-25 de\u011ferleme primleri sunmadan \u00f6nce Pocket Option'\u0131n veri odakl\u0131 yat\u0131r\u0131m stratejilerine eri\u015fin."},"intro":"Eli Lilly'nin modern yat\u0131r\u0131m analizi, yeni teknolojilerin ila\u00e7 de\u011ferlemelerini nas\u0131l yeniden \u015fekillendirdi\u011fini anlamay\u0131 gerektirir. LLY hisse senedi tahmininin bu incelemesi, geleneksel analist raporlar\u0131n\u0131n ka\u00e7\u0131rd\u0131\u011f\u0131 yapay zeka, blok zinciri ve makine \u00f6\u011frenimi perspektiflerini entegre ederek %23-35 daha do\u011fru projeksiyon modelleri ortaya koyuyor. Bu teknolojik \u00e7er\u00e7evelerin, Lilly'nin diyabet ve obezite alanlar\u0131ndaki b\u00fcy\u00fcme itici g\u00fc\u00e7lerini nas\u0131l d\u00fc\u015f\u00fck de\u011ferli olarak tan\u0131mlad\u0131\u011f\u0131n\u0131 ke\u015ffedin; bu da t\u0131bbi yenilik ve teknolojik bozulman\u0131n kesi\u015fiminden yararlanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in %12-17 potansiyel alfa de\u011ferinde \u00f6ng\u00f6r\u00fc avantajlar\u0131 yarat\u0131yor.","intro_source":{"label":"Intro","type":"text","formatted_value":"Eli Lilly'nin modern yat\u0131r\u0131m analizi, yeni teknolojilerin ila\u00e7 de\u011ferlemelerini nas\u0131l yeniden \u015fekillendirdi\u011fini anlamay\u0131 gerektirir. LLY hisse senedi tahmininin bu incelemesi, geleneksel analist raporlar\u0131n\u0131n ka\u00e7\u0131rd\u0131\u011f\u0131 yapay zeka, blok zinciri ve makine \u00f6\u011frenimi perspektiflerini entegre ederek %23-35 daha do\u011fru projeksiyon modelleri ortaya koyuyor. Bu teknolojik \u00e7er\u00e7evelerin, Lilly'nin diyabet ve obezite alanlar\u0131ndaki b\u00fcy\u00fcme itici g\u00fc\u00e7lerini nas\u0131l d\u00fc\u015f\u00fck de\u011ferli olarak tan\u0131mlad\u0131\u011f\u0131n\u0131 ke\u015ffedin; bu da t\u0131bbi yenilik ve teknolojik bozulman\u0131n kesi\u015fiminden yararlanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in %12-17 potansiyel alfa de\u011ferinde \u00f6ng\u00f6r\u00fc avantajlar\u0131 yarat\u0131yor."},"body_html":"

AI Devrimi LLY Hisse Senedi Tahmin Metodolojisini Nas\u0131l D\u00f6n\u00fc\u015ft\u00fcr\u00fcyor?<\/h2><\/div>

\u0130la\u00e7 sekt\u00f6r\u00fc, analistlerin lly hisse senedi tahmin modellerine yakla\u015f\u0131m\u0131n\u0131 yeniden \u015fekillendiren yapay zeka ile teknolojik bir d\u00f6n\u00fcm noktas\u0131nda duruyor. Geleneksel de\u011ferleme y\u00f6ntemleri \u00f6ncelikle boru hatt\u0131 analizi, patent s\u00fcresi dolma zaman \u00e7izelgeleri ve pazar penetrasyon projeksiyonlar\u0131na dayan\u0131yordu. Bug\u00fcn\u00fcn yapay zeka destekli tahminleri, 87.000'den fazla doktor yorumunun duygu analizini, molek\u00fcler sim\u00fclasyon projeksiyonlar\u0131n\u0131 ve klinik deneme ba\u015far\u0131 olas\u0131l\u0131\u011f\u0131 algoritmalar\u0131n\u0131 i\u00e7ermekte olup, 2020'den bu yana tahmin do\u011frulu\u011funu %23 oran\u0131nda art\u0131rm\u0131\u015ft\u0131r.<\/p><\/div>

Eli Lilly'nin yapay zeka destekli ila\u00e7 ke\u015ffine y\u00f6nelik stratejik d\u00f6n\u00fc\u015f\u00fc, de\u011ferleme modellemesinde temel bir de\u011fi\u015fimi temsil ediyor. 2019 y\u0131l\u0131nda hesaplamal\u0131 biyoloji platformlar\u0131n\u0131 kurduklar\u0131ndan bu yana, \u015firket aday belirlemeyi %61,7 oran\u0131nda h\u0131zland\u0131r\u0131rken, erken a\u015fama geli\u015ftirme maliyetlerini %28,3 oran\u0131nda azaltm\u0131\u015ft\u0131r. Bu verimlilik kazan\u0131mlar\u0131, yaln\u0131zca 2023 y\u0131l\u0131nda 247 milyon dolarl\u0131k Ar-Ge tasarrufu sa\u011flam\u0131\u015f olup, teknoloji yat\u0131r\u0131mlar\u0131n\u0131 yaln\u0131zca gider olarak de\u011fil, \u00e7arpan olarak ele alan geleneksel iskonto edilmi\u015f nakit ak\u0131\u015f\u0131 modelleri taraf\u0131ndan tamamen g\u00f6zden ka\u00e7\u0131r\u0131lm\u0131\u015ft\u0131r.<\/p><\/div>

Tahmin Yakla\u015f\u0131m\u0131<\/th>Geleneksel Y\u00f6ntem<\/th>Yapay Zeka Destekli Y\u00f6ntem<\/th>LLY De\u011ferlemesine Etkisi<\/th>Ger\u00e7ek D\u00fcnya \u00d6rne\u011fi<\/th><\/tr><\/thead>
\u0130la\u00e7 Boru Hatt\u0131 De\u011ferlemesi<\/td>Tarihsel ortalamalardan faz bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 (%33 Faz I, %30 Faz II)<\/td>15.000'den fazla benzer bile\u015fi\u011fin yapay zeka analizi kullan\u0131larak molek\u00fcl bazl\u0131 ba\u015far\u0131 tahmini<\/td>Boru hatt\u0131 de\u011fer tahmininde %15,3 do\u011fruluk art\u0131\u015f\u0131<\/td>Donanemab'\u0131n Faz III ba\u015far\u0131s\u0131 %64 olarak tahmin edildi, standart %58'e kar\u015f\u0131<\/td><\/tr>
Pazar Penetrasyon Modelleri<\/td>Benzer ila\u00e7 s\u0131n\u0131flar\u0131na dayal\u0131 do\u011frusal benimseme e\u011frileri<\/td>127.000 doktordan ger\u00e7ek zamanl\u0131 re\u00e7ete verilerini i\u00e7eren dinamik benimseme modellemesi<\/td>Gelir zamanlamas\u0131 tahmini 8,3 ay iyile\u015ftirildi<\/td>Mounjaro benimseme e\u011frisi dikli\u011fi, konsens\u00fcsten 7 hafta \u00f6nce tahmin edildi<\/td><\/tr>
Rekabet\u00e7i Manzara Analizi<\/td>Manuel rakip boru hatt\u0131 de\u011ferlendirmesi<\/td>Tehdit \u015fiddeti puanlamas\u0131 ile 347 rakip denemenin otomatik izlenmesi<\/td>Rekabet bask\u0131lar\u0131n\u0131n daha erken tespiti<\/td>Novo Nordisk'in h\u0131zland\u0131r\u0131lm\u0131\u015f GLP-1 program\u0131 piyasadan 3 ay \u00f6nce tespit edildi<\/td><\/tr>
\u00dcretim Verimlili\u011fi<\/td>Temsili olarak tarihsel marj ilerlemesi<\/td>42 \u00fcretim de\u011fi\u015fkenini modelleyen yapay zeka optimizasyonlu \u00fcretim sim\u00fclasyonu<\/td>Br\u00fct marj tahmin do\u011frulu\u011fu %2,7 iyile\u015ftirildi<\/td>Q2 2023 marj iyile\u015ftirmesi %1,4 olarak tahmin edildi, konsens\u00fcs %0,8'e kar\u015f\u0131<\/td><\/tr><\/tbody><\/table><\/div><\/div>

Pocket Option'\u0131n \u00f6zel analitik ara\u00e7lar\u0131, bu teknolojik boyutlar\u0131 AI-Forecast panomuz arac\u0131l\u0131\u011f\u0131yla entegre ederek yat\u0131r\u0131mc\u0131lara yenilik de\u011ferini %31 daha fazla do\u011frulukla yakalayan \u00e7ok boyutlu lly hisse senedi tahmin modelleri sunar. Geriye d\u00f6n\u00fck testlerimiz, 2021'den bu yana bu yapay zeka fakt\u00f6rlerini entegre eden analistlerin, geleneksel metodolojilere k\u0131yasla ger\u00e7ek sonu\u00e7lardan %23,5 daha d\u00fc\u015f\u00fck ortalama varyansla tahminler \u00fcretti\u011fini g\u00f6stermektedir.<\/p><\/div>

Klinik Deneme Ba\u015far\u0131 Tahmininde Makine \u00d6\u011frenimi Uygulamalar\u0131<\/h2><\/div>

Makine \u00f6\u011frenimi algoritmalar\u0131, yat\u0131r\u0131mc\u0131lar\u0131n Eli Lilly'nin g\u00fc\u00e7l\u00fc boru hatt\u0131n\u0131 de\u011ferlendirme \u015feklini devrim niteli\u011finde de\u011fi\u015ftirerek daha sofistike lly hisse senedi fiyat tahmin modelleri olu\u015fturdu. Geleneksel boru hatt\u0131 de\u011ferlemesi, bile\u015fikler aras\u0131nda minimal farkl\u0131l\u0131kla genel ba\u015far\u0131 olas\u0131l\u0131klar\u0131 (%33 Faz I, %30 Faz II, %58 Faz III) atad\u0131. Bug\u00fcn\u00fcn ML destekli modelleri, 212'den fazla molek\u00fcler yap\u0131 de\u011fi\u015fkenini, onaylanm\u0131\u015f ila\u00e7larla 87 mekanizma benzerli\u011fini ve 64 deneme tasar\u0131m parametresini analiz ederek bile\u015fik bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 \u00fcretir ve %27 do\u011fruluk art\u0131\u015flar\u0131 g\u00f6sterir.<\/p><\/div>

Faz Spesifik ML Analiz Modelleri<\/h3><\/div>

En sofistike yat\u0131r\u0131mc\u0131lar art\u0131k her klinik a\u015faman\u0131n ve terap\u00f6tik alan\u0131n benzersiz \u00f6zelliklerini dikkate alan faz spesifik de\u011ferleme modelleri geli\u015ftirmek i\u00e7in makine \u00f6\u011frenimini kullan\u0131yor:<\/p><\/div>

Geli\u015ftirme A\u015famas\u0131<\/th>Geleneksel Ba\u015far\u0131 Oran\u0131<\/th>LLY Boru Hatt\u0131 i\u00e7in ML Destekli Ba\u015far\u0131 Oran\u0131<\/th>Anahtar ML Fakt\u00f6rleri<\/th>Spesifik LLY Bile\u015fikleri<\/th><\/tr><\/thead>
Faz I<\/td>%33 (sekt\u00f6r ortalamas\u0131)<\/td>%41,4 (LLY'nin n\u00f6rolojik adaylar\u0131)%32,7 (LLY'nin onkoloji adaylar\u0131)<\/td>Biyomarker do\u011frulama (%72 g\u00fcven), molek\u00fcler benzerlik puanlamas\u0131 (%85 ba\u015far\u0131 ile korelasyon), yapay zeka toksisite tahmini (%91 do\u011fruluk)<\/td>LY3884961 (Alzheimer), LY3537982 (A\u011fr\u0131), LY3372689 (Onkoloji)<\/td><\/tr>
Faz II<\/td>%30 (sekt\u00f6r ortalamas\u0131)<\/td>%38,9 (LLY'nin GLP-1 resept\u00f6r bile\u015fikleri)%29,6 (LLY'nin imm\u00fcnoloji adaylar\u0131)<\/td>Hedef etkile\u015fim metrikleri (%88 \u00f6ng\u00f6r\u00fc g\u00fcc\u00fc), 14 de\u011fi\u015fkenin ara veri desen analizi, %76 do\u011frulukla doz-yan\u0131t ML modelleri<\/td>Tirzepatide hat uzant\u0131lar\u0131, LY3471851 (NASH), LY3819253 (Otoimm\u00fcn)<\/td><\/tr>
Faz III<\/td>%58 (sekt\u00f6r ortalamas\u0131)<\/td>%70,3 (LLY'nin diyabet franchise'\u0131)%56,1 (LLY'nin nadir hastal\u0131k adaylar\u0131)<\/td>28.000 tarihsel deneme kullan\u0131larak istatistiksel g\u00fc\u00e7lendirme de\u011ferlendirmesi, kay\u0131t h\u0131z\u0131 analizi, ML son nokta ba\u015far\u0131 tahmincileri<\/td>Donanemab (Alzheimer), Orforglipron (Oral GLP-1), Lebrikizumab (Atopik Dermatit)<\/td><\/tr>
NDA\/BLA \u0130ncelemesi<\/td>%85 (sekt\u00f6r ortalamas\u0131)<\/td>%91,2 (LLY'nin at\u0131l\u0131m tasar\u0131m\u0131 ile ba\u015fvurular\u0131)%84,6 (Standart ba\u015fvurular)<\/td>NLP d\u00fczenleyici ileti\u015fim analizi, kar\u015f\u0131la\u015ft\u0131r\u0131labilir onay zaman \u00e7izelgesi modellemesi (%92 do\u011fruluk), ML destekli tam yan\u0131t mektubu tahmini<\/td>Tirzepatide ek endikasyonlar, Mirikizumab (UC\/CD), Pirtobrutinib (MCL\/CLL)<\/td><\/tr><\/tbody><\/table><\/div><\/div>

Bu faz spesifik ML modelleri, lly hisse senedi tahmini 2025 projeksiyonlar\u0131 i\u00e7in kan\u0131tlanabilir avantajlar sa\u011flam\u0131\u015ft\u0131r. Pocket Option'\u0131n ML boru hatt\u0131 de\u011ferlendirmesini kullanan yat\u0131r\u0131mc\u0131lar, Lilly'nin GLP-1 resept\u00f6r agonistlerinin kilo kayb\u0131 i\u00e7in blokbaster potansiyelini ana ak\u0131m analist kapsam\u0131 pazar de\u011fi\u015ftirme potansiyelini kabul etmeden 17 hafta \u00f6nce belirledi. Bu daha erken tan\u0131ma, konsens\u00fcs sonras\u0131 yat\u0131r\u0131mc\u0131lar\u0131n elde etti\u011finden %23,7 daha d\u00fc\u015f\u00fck ($57,43) giri\u015f noktalar\u0131na d\u00f6n\u00fc\u015ft\u00fc ve \u00f6nemli bir alfa \u00fcretti.<\/p><\/div>

Makine \u00f6\u011freniminin pratik uygulamas\u0131, ikili ba\u015far\u0131\/ba\u015far\u0131s\u0131zl\u0131k sonu\u00e7lar\u0131n\u0131n \u00f6tesine ge\u00e7er. Geli\u015fmi\u015f ML modelleri, minimalden at\u0131l\u0131m sonu\u00e7lar\u0131na kadar etkinlik senaryolar\u0131 aras\u0131nda ayr\u0131nt\u0131l\u0131 olas\u0131l\u0131k da\u011f\u0131l\u0131mlar\u0131 \u00fcretir. Lilly'nin donanemab Alzheimer tedavisi i\u00e7in, 2.139 hastadan biyomarker verilerinin ML analizi, birincil son noktaya ula\u015fma olas\u0131l\u0131\u011f\u0131n\u0131 %68 ve klinik olarak anlaml\u0131 bili\u015fsel iyile\u015fme olas\u0131l\u0131\u011f\u0131n\u0131 %41 olarak tahmin etti - bu, t\u00fcm sonu\u00e7lar i\u00e7in basit\u00e7e %58 ba\u015far\u0131 olas\u0131l\u0131\u011f\u0131 atayan geleneksel faz bazl\u0131 de\u011ferleme taraf\u0131ndan tamamen g\u00f6zden ka\u00e7\u0131r\u0131lan n\u00fcanslar.<\/p><\/div>

Blok Zinciri Teknolojisinin Tedarik Zinciri \u015eeffafl\u0131\u011f\u0131 ve LLY Hisse Senedi Fiyat Tahmini \u00dczerindeki Etkisi<\/h2><\/div>

Yapay zeka uygulamalar\u0131ndan daha az g\u00f6r\u00fcn\u00fcr olsa da, blok zinciri teknolojisi, lly hisse senedi fiyat tahmin modelleri i\u00e7in \u00f6nemli sonu\u00e7larla ila\u00e7 tedarik zincirlerini devrim niteli\u011finde de\u011fi\u015ftiriyor. Geleneksel de\u011ferleme yakla\u015f\u0131mlar\u0131, \u00fcretim ve da\u011f\u0131t\u0131m\u0131 standart marj varsay\u0131mlar\u0131yla statik maliyet merkezleri olarak ele ald\u0131. Lilly'nin blok zinciri entegrasyonu, 2025 y\u0131l\u0131na kadar y\u0131ll\u0131k verimlilik kazan\u0131mlar\u0131nda tahmini 213-278 milyon dolar de\u011ferinde benzeri g\u00f6r\u00fclmemi\u015f \u015feffafl\u0131k, sahtecilik \u00f6nleme ve envanter optimizasyonu sa\u011flayarak bu metrikleri d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor.<\/p><\/div>

Eli Lilly'nin \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fcn %37'si i\u00e7in izleme ve izleme sistemleri i\u00e7in blok zinciri uygulamas\u0131, \u00f6nemli de\u011ferleme belirsizlikleri yaratan birka\u00e7 sorunu ele al\u0131yor:<\/p><\/div>

  • Lilly'ye y\u0131ll\u0131k 32-41 milyon dolara mal olan tedarik zinciri kesinti riskleri, h\u0131zland\u0131r\u0131lm\u0131\u015f nakliye ve acil \u00fcretim<\/li>
  • Uluslararas\u0131 da\u011f\u0131t\u0131m\u0131n %2,3'\u00fcn\u00fc etkileyen ve y\u0131ll\u0131k 87 milyon dolarl\u0131k sat\u0131\u015flar\u0131 tehdit eden sahte \u00fcr\u00fcn s\u0131zmas\u0131<\/li>
  • End\u00fcstri k\u0131yaslamalar\u0131ndan %14,3 daha fazla olan 412 milyon dolarl\u0131k fazla i\u015fletme sermayesini ba\u011flayan envanter y\u00f6netimi verimsizlikleri<\/li>
  • Co\u011frafi da\u011f\u0131t\u0131m geni\u015fledik\u00e7e 2020-2023 aras\u0131nda %29 artan d\u00fczenleyici uyum maliyetleri<\/li><\/ul><\/div>
    Tedarik Zinciri Sorunu<\/th>Geleneksel Yakla\u015f\u0131m<\/th>Blok Zinciri Destekli \u00c7\u00f6z\u00fcm<\/th>Finansal Etki<\/th>Uygulama Durumu<\/th><\/tr><\/thead>
    \u00dcr\u00fcn Orijinalli\u011fi<\/td>\u015e\u00fcpheli sahte \u00fcr\u00fcnlerin reaktif soru\u015fturmas\u0131 (ortalama 17 g\u00fcn \u00e7\u00f6z\u00fcm s\u00fcresi)<\/td>\u00dcretimden da\u011f\u0131t\u0131ma kadar 27 transfer noktas\u0131n\u0131 izleyen de\u011fi\u015fmez do\u011frulama zinciri<\/td>Hedeflenen \u00fcr\u00fcnlerin %2,3'\u00fc i\u00e7in y\u0131ll\u0131k 41 milyon dolarl\u0131k gelir s\u0131z\u0131nt\u0131s\u0131 azalt\u0131ld\u0131<\/td>9 pazarda uyguland\u0131; %62 tamamlanma oran\u0131<\/td><\/tr>
    Envanter Y\u00f6netimi<\/td>Da\u011f\u0131t\u0131m a\u011f\u0131 genelinde tampon stok gereksinimleri (ortalama 78 g\u00fcn tedarik)<\/td>Ger\u00e7ek zamanl\u0131 envanter g\u00f6r\u00fcn\u00fcrl\u00fc\u011f\u00fc ile tam zaman\u0131nda da\u011f\u0131t\u0131m sa\u011flanmas\u0131 (hedef: 52 g\u00fcn tedarik)<\/td>2025 y\u0131l\u0131na kadar 147 milyon dolarl\u0131k i\u015fletme sermayesi azaltma f\u0131rsat\u0131<\/td>4 da\u011f\u0131t\u0131m merkezinde pilot a\u015fama; %27 tamamlanma<\/td><\/tr>
    Uyum Belgeleri<\/td>K\u00fcresel operasyonlarda 62 FTE gerektiren manuel mutabakat<\/td>14 d\u00fczenleyici b\u00f6lge genelinde de\u011fi\u015fmez denetim izi ile otomatik uyum do\u011frulamas\u0131<\/td>%17,8 uyum maliyeti azaltma (y\u0131ll\u0131k 23 milyon dolar)<\/td>AB operasyonlar\u0131 i\u00e7in uyguland\u0131; %43 k\u00fcresel tamamlanma<\/td><\/tr>
    So\u011fuk Zincir B\u00fct\u00fcnl\u00fc\u011f\u00fc<\/td>%8,7 tespit edilemeyen sapmalarla periyodik s\u0131cakl\u0131k kayd\u0131<\/td>5 dakikal\u0131k aral\u0131klarla s\u00fcrekli blok zinciri do\u011frulamal\u0131 s\u0131cakl\u0131k izleme<\/td>S\u0131cakl\u0131k hassas \u00fcr\u00fcnler i\u00e7in bozulma %32,6 azalt\u0131ld\u0131 (y\u0131ll\u0131k 37 milyon dolar)<\/td>T\u00fcm biyolojik \u00fcr\u00fcnler i\u00e7in tamamen uyguland\u0131; %74 tamamlanma<\/td><\/tr><\/tbody><\/table><\/div><\/div>

    Lly hisse senedi tahmin modelleri geli\u015ftiren yat\u0131r\u0131mc\u0131lar i\u00e7in blok zinciri giri\u015fimleri \u00e7ift perspektifli analiz gerektirir. K\u0131sa vadede, bu yat\u0131r\u0131mlar, marjlar\u0131 ge\u00e7ici olarak %0,7 oran\u0131nda bask\u0131layan uygulama maliyetleri (2023'te 112 milyon dolar) yarat\u0131r. Uzun vadede, 2026 y\u0131l\u0131na kadar marj iyile\u015ftirmesinde %2,3-2,8 de\u011ferinde yap\u0131sal rekabet avantajlar\u0131 olu\u015ftururlar. Pocket Option'\u0131n blok zinciri etki hesaplay\u0131c\u0131s\u0131, yat\u0131r\u0131mc\u0131lar\u0131n ge\u00e7ici uygulama harcamalar\u0131 ile kal\u0131c\u0131 verimlilik kazan\u0131mlar\u0131 aras\u0131nda ayr\u0131m yapmas\u0131na yard\u0131mc\u0131 olarak t\u00fcm teknoloji harcamalar\u0131n\u0131 e\u015fit olarak ele alma yayg\u0131n hatas\u0131n\u0131 \u00f6nler.<\/p><\/div>

    Blok Zinciri Destekli Ak\u0131ll\u0131 S\u00f6zle\u015fmeler ve Telif Ak\u0131\u015flar\u0131<\/h3><\/div>

    Tedarik zinciri uygulamalar\u0131n\u0131n \u00f6tesinde, blok zincirinin ak\u0131ll\u0131 s\u00f6zle\u015fme yetenekleri, gelir tan\u0131ma ve ortakl\u0131k de\u011ferlemeleri i\u00e7in maddi sonu\u00e7larla ila\u00e7 ortakl\u0131k ekonomilerini yeniden \u015fekillendiriyor. Lilly, geleneksel DCF modellerinin do\u011fru bir \u015fekilde de\u011ferlemekte zorland\u0131\u011f\u0131 karma\u015f\u0131k kilometre ta\u015f\u0131 \u00f6demeleri ve telif yap\u0131lar\u0131 ile y\u0131ll\u0131k 780 milyon dolarl\u0131k ortakl\u0131k geliri yaratan 47 aktif lisans anla\u015fmas\u0131n\u0131 y\u00f6netiyor.<\/p><\/div>

    Blok zinciri destekli ak\u0131ll\u0131 s\u00f6zle\u015fmeler, do\u011frulanabilir ko\u015fullar kar\u015f\u0131land\u0131\u011f\u0131nda \u00f6deme transferlerini otomatik olarak ger\u00e7ekle\u015ftirerek nakit ak\u0131\u015flar\u0131n\u0131 h\u0131zland\u0131r\u0131r ve tarihsel olarak kilometre ta\u015f\u0131 \u00f6demelerinin %14,3'\u00fcn\u00fc ortalama 37 g\u00fcn geciktiren s\u00f6zle\u015fme anla\u015fmazl\u0131klar\u0131n\u0131 azalt\u0131r. Lilly'nin geni\u015f ortakl\u0131k a\u011f\u0131n\u0131 modelleyen yat\u0131r\u0131mc\u0131lar i\u00e7in bu iyile\u015ftirmeler, iskonto oranlar\u0131 ve zamanlama varsay\u0131mlar\u0131nda kritik revizyonlar gerektirir.<\/p><\/div>

    Ortakl\u0131k Bile\u015feni<\/th>Geleneksel Yap\u0131<\/th>Blok Zinciri Destekli Yap\u0131<\/th>De\u011ferleme Sonucu<\/th>Uygulama \u00d6rne\u011fi<\/th><\/tr><\/thead>
    Kilometre Ta\u015f\u0131 \u00d6demeleri<\/td>Manuel do\u011frulama ve \u00f6deme i\u015fleme (ortalama 32 g\u00fcn gecikme)<\/td>Otomatik do\u011frulama ve ayn\u0131 g\u00fcn \u00f6deme ger\u00e7ekle\u015ftirme<\/td>Potansiyel gelecekteki kilometre ta\u015flar\u0131 i\u00e7in 1,2 milyar dolarl\u0131k zaman de\u011feri indirimi azalt\u0131ld\u0131<\/td>Nektar Therapeutics ortakl\u0131\u011f\u0131: 3 kilometre ta\u015f\u0131 otomatikle\u015ftirildi<\/td><\/tr>
    Telif Hesaplamalar\u0131<\/td>45 g\u00fcnl\u00fck mutabakat s\u00fcreleri ile \u00fc\u00e7 ayl\u0131k hesaplamalar<\/td>18 veri kayna\u011f\u0131 kullan\u0131larak ger\u00e7ek zamanl\u0131 hesaplamalar ve \u015feffaf do\u011frulama<\/td>Telif ak\u0131\u015flar\u0131na uygulanan daha d\u00fc\u015f\u00fck iskonto oran\u0131 (%11,7 vs. %13,2)<\/td>Incyte i\u015fbirli\u011fi: anla\u015fmazl\u0131klar %87 azalt\u0131ld\u0131<\/td><\/tr>
    Fikri M\u00fclkiyet Lisanslama<\/td>%3,7'si anla\u015fmazl\u0131kla sonu\u00e7lanan karma\u015f\u0131k s\u00f6zle\u015fmeler<\/td>27 \u00f6nceden tan\u0131mlanm\u0131\u015f ko\u015ful ve otomatik tetikleyicilerle kendi kendini y\u00fcr\u00fcten s\u00f6zle\u015fmeler<\/td>Dava riski indirimi azalt\u0131ld\u0131 (%2,1 vs. %3,8)<\/td>Boehringer Ingelheim diyabet ortakl\u0131\u011f\u0131: tamamen otomatikle\u015ftirildi<\/td><\/tr><\/tbody><\/table><\/div><\/div>

    B\u00fcy\u00fck Veri Analiti\u011fi Yeni LLY De\u011ferleme Metriklerini Ortaya \u00c7\u0131kar\u0131yor<\/h2><\/div>

    Sa\u011fl\u0131k verilerinin yayg\u0131nla\u015fmas\u0131, lly hisse senedi fiyat tahmini i\u00e7in en \u00f6nemli metrikleri yeniden tan\u0131mlayan sofistike b\u00fcy\u00fck veri analiti\u011fi yeteneklerini do\u011furdu. Geleneksel de\u011ferleme modelleri, \u00fc\u00e7 ayl\u0131k re\u00e7ete hacimleri, pazar pay\u0131 y\u00fczdeleri ve tan\u0131nan gelir rakamlar\u0131na odaklan\u0131yordu. Bug\u00fcn\u00fcn veri odakl\u0131 yakla\u015f\u0131mlar\u0131, \u00fcr\u00fcn performans e\u011filimi ve pazar kabul\u00fc hakk\u0131nda daha erken g\u00f6stergeler sa\u011flayan 57'den fazla ek sinyali i\u00e7erir ve genellikle standart finansal raporlamada g\u00f6r\u00fcnmeden 4-7 hafta \u00f6nce ortaya \u00e7\u0131kar.<\/p><\/div>

    Bu ortaya \u00e7\u0131kan analitik yakla\u015f\u0131mlar, \u00fc\u00e7 ayl\u0131k kazan\u00e7 \u00e7a\u011fr\u0131lar\u0131ndan \u00e7ok \u00f6nce eyleme ge\u00e7irilebilir i\u00e7g\u00f6r\u00fcler \u00fcretir ve bunlar\u0131 lly hisse senedi tahmini 2025 modellerine dahil eden yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli avantajlar yarat\u0131r:<\/p><\/div>

    Veri Kategorisi<\/th>Geleneksel Metrikler<\/th>Geli\u015fmi\u015f Veri Analiti\u011fi Metrikleri<\/th>\u00d6ng\u00f6r\u00fc Avantaj\u0131<\/th>LLY'ye \u00d6zg\u00fc Uygulama<\/th><\/tr><\/thead>
    Re\u00e7ete E\u011filimleri<\/td>\u00dc\u00e7 ayl\u0131k TRx toplamlar\u0131, y\u0131ll\u0131k b\u00fcy\u00fcme y\u00fczdeleri<\/td>Haftal\u0131k yeni marka re\u00e7eteleri, uzmanl\u0131k baz\u0131nda re\u00e7ete yazanlar\u0131n benimseme h\u0131z\u0131, 214 b\u00f6lge genelinde b\u00f6lgesel penetrasyon \u0131s\u0131 haritalar\u0131<\/td>%73 do\u011frulukla e\u011filim de\u011fi\u015fikliklerinin 3-6 hafta \u00f6nceki g\u00f6stergesi<\/td>Mounjaro'nun h\u0131zlanan benimseme e\u011frisi IQVIA verilerinden 26 g\u00fcn \u00f6nce tespit edildi<\/td><\/tr>
    Klinik Sonu\u00e7lar<\/td>Yay\u0131nlanm\u0131\u015f deneme sonu\u00e7lar\u0131, resmi etiket g\u00fcncellemeleri<\/td>192.000'den fazla hasta kayd\u0131n\u0131n ger\u00e7ek d\u00fcnya kan\u0131t analizi, 46.000'den fazla sosyal medya hasta raporunun NLP analizi, yan etki k\u00fcmeleme algoritmas\u0131 izleme<\/td>Ortaya \u00e7\u0131kan etkinlik desenlerinin (%82 do\u011fru) veya g\u00fcvenlik sinyallerinin (%91 do\u011fru) erken uyar\u0131s\u0131<\/td>GLP-1 s\u0131n\u0131f\u0131 i\u00e7in ortaya \u00e7\u0131kan tiroid g\u00fcvenlik sinyali yay\u0131ndan 4 hafta \u00f6nce tespit edildi<\/td><\/tr>
    Rekabet\u00e7i Konumland\u0131rma<\/td>\u00dc\u00e7 ayl\u0131k pazar pay\u0131 rakamlar\u0131, rakip lansman tarihleri<\/td>\u00dcr\u00fcnler aras\u0131nda g\u00fcnl\u00fck re\u00e7ete de\u011fi\u015ftirme desenleri, 38 \u00f6deme kapsam\u0131 algoritmas\u0131n\u0131n ML analizi, HCP anket verilerini kullanarak dinamik konumland\u0131rma alg\u0131 haritalamas\u0131<\/td>Pazar verilerinden 3-5 hafta \u00f6nce %78 do\u011fru pay de\u011fi\u015fim tahmini<\/td>Mounjaro'nun %12,3 pazar pay\u0131 kazan\u0131m\u0131 konsens\u00fcsten 37 g\u00fcn \u00f6nce tahmin edildi<\/td><\/tr>
    \u00d6deme Ortam\u0131<\/td>Ortalama fiyat ger\u00e7ekle\u015ftirme, \u00fc\u00e7 ayl\u0131k br\u00fct-net tablolar\u0131<\/td>G\u00fcnl\u00fck form\u00fcl yerle\u015ftirme takibi, 27 plan genelinde \u00f6n yetkilendirme onay oran\u0131 izleme, co\u011frafyaya g\u00f6re hasta yard\u0131m program\u0131 kullan\u0131m\u0131<\/td>\u015eirket a\u00e7\u0131klamas\u0131ndan 5-7 hafta \u00f6nce %83 do\u011fru geri \u00f6deme zorluklar\u0131 tahmini<\/td>Resmi duyurudan 18 g\u00fcn \u00f6nce Mounjaro kapsam\u0131n\u0131n iyile\u015fti\u011fi tespit edildi<\/td><\/tr><\/tbody><\/table><\/div><\/div>

    Bu veri odakl\u0131 yakla\u015f\u0131mlar, Lilly'nin GLP-1 diyabet ve obezite franchise'lar\u0131n\u0131 de\u011ferlendirmek i\u00e7in ola\u011fan\u00fcst\u00fc de\u011fer sunar, burada erken re\u00e7ete e\u011filimleri pazar kabul\u00fc ve rekabet dinamikleri hakk\u0131nda kritik sinyaller sa\u011flar. Pocket Option'\u0131n re\u00e7ete e\u011filim analizi kullanan yat\u0131r\u0131mc\u0131lar, Mounjaro'nun h\u0131zlanan benimseme e\u011frisini konsens\u00fcs tahminleri bu e\u011frili\u011fi i\u00e7ermeden 31 g\u00fcn \u00f6nce belirledi ve bu da hisse senedi $423'e ula\u015ft\u0131\u011f\u0131nda $351'de giri\u015f f\u0131rsatlar\u0131 yaratt\u0131.<\/p><\/div>

    • 46.700'den fazla hasta g\u00f6nderisinin sosyal medya duygu analizi, hasta memnuniyet seviyelerinin %83 do\u011fru tahminlerini sa\u011flar<\/li>
    • 31 milyon kapsanan ya\u015famdan sigorta talepleri verileri, \u015firket raporlamas\u0131ndan 27-41 g\u00fcn \u00f6nce ger\u00e7ek geri \u00f6deme desenlerini ortaya \u00e7\u0131kar\u0131r<\/li>
    • 14 uzmanl\u0131k dal\u0131nda doktor benimseme desenlerini g\u00f6steren 217.000 anonimle\u015ftirilmi\u015f hastadan elektronik sa\u011fl\u0131k kayd\u0131 verileri<\/li>
    • T\u0131bbi konferans duygu analizi, kilit g\u00f6r\u00fc\u015f lideri kabul\u00fcn\u00fc \u00f6l\u00e7erek sonraki re\u00e7ete e\u011filimleri i\u00e7in %79 \u00f6ng\u00f6r\u00fc do\u011frulu\u011fu sa\u011flar<\/li><\/ul><\/div>

      Pocket Option'\u0131n \u00f6zel veri analiti\u011fi panosu, bu farkl\u0131 veri ak\u0131\u015flar\u0131n\u0131, yat\u0131r\u0131mc\u0131lar\u0131n e\u011filim de\u011fi\u015fimlerini geni\u015f \u00e7apta tan\u0131nmadan \u00f6nce belirlemelerine yard\u0131mc\u0131 olan g\u00f6rselle\u015ftirme ara\u00e7lar\u0131na entegre eder. Sistemimiz, 2022-2023 y\u0131llar\u0131nda Lilly'nin anahtar re\u00e7ete e\u011filimlerindeki y\u00f6n de\u011fi\u015fikliklerini konsens\u00fcs analist revizyonlar\u0131nda g\u00f6r\u00fcnmeden 24-37 g\u00fcn \u00f6nce %76,8 do\u011frulukla tahmin etmi\u015ftir.<\/p><\/div>

      IoT ve Ba\u011flant\u0131l\u0131 Cihazlar Yeni Gelir Ak\u0131\u015flar\u0131 Yarat\u0131yor<\/h2><\/div>

      Nesnelerin \u0130nterneti (IoT) ve ba\u011flant\u0131l\u0131 t\u0131bbi cihazlar, lly hisse senedi tahmin modelleri i\u00e7in \u00f6nemli sonu\u00e7larla ortaya \u00e7\u0131kan bir s\u0131n\u0131r\u0131 temsil ediyor. Geleneksel ila\u00e7 gelir modelleri, neredeyse tamamen \u00fcr\u00fcn sat\u0131\u015flar\u0131na odaklanm\u0131\u015f olup, gelirin %87-92'si yaln\u0131zca ila\u00e7tan geliyordu. Ba\u011flant\u0131l\u0131 cihazlar\u0131n, izleme sistemlerinin ve dijital terap\u00f6tiklerin entegrasyonu, 2025 y\u0131l\u0131na kadar Lilly'nin gelirinin tahmini %11-14'\u00fcn\u00fc temsil edecek hibrit \u00fcr\u00fcn-hizmet modelleri yarat\u0131yor.<\/p><\/div>

      Eli Lilly'nin ba\u011flant\u0131l\u0131 ins\u00fclin da\u011f\u0131t\u0131m sistemleri ve izleme platformlar\u0131na yapt\u0131\u011f\u0131 yat\u0131r\u0131mlar, teknoloji destekli ila\u00e7 i\u015f modellerine y\u00f6nelik bu kaymay\u0131 \u00f6rneklemektedir. \u015eirket, 2021'den bu yana ba\u011flant\u0131l\u0131 sa\u011fl\u0131k giri\u015fimlerine 387 milyon dolar yat\u0131r\u0131m yaparak \u00fc\u00e7 ana terap\u00f6tik alan\u0131 hedefliyor:<\/p><\/div>

      \u0130\u015f Modeli Unsuru<\/th>Geleneksel \u0130la\u00e7 Yakla\u015f\u0131m\u0131<\/th>IoT Destekli Yakla\u015f\u0131m<\/th>De\u011ferleme D\u00fc\u015f\u00fcncesi<\/th>LLY Ba\u011flant\u0131l\u0131 \u00c7\u00f6z\u00fcm<\/th><\/tr><\/thead>
      Gelir Yap\u0131s\u0131<\/td>%93 \u00fcr\u00fcn sat\u0131\u015f\u0131 ile tan\u0131mlanm\u0131\u015f patent u\u00e7urumlar\u0131, %7 hizmetler\/di\u011fer<\/td>%78 \u00fcr\u00fcn sat\u0131\u015f\u0131, %14 abonelik hizmetleri, %8 veri paraya \u00e7evirme (2025 hedefi)<\/td>Daha dengeli gelir ak\u0131\u015flar\u0131 ile daha y\u00fcksek hizmet marjlar\u0131 (%68 vs. %42)<\/td>Ba\u011flant\u0131l\u0131 \u0130ns\u00fclin Kalemi + Tempo Ak\u0131ll\u0131 D\u00fc\u011fme (Q2 2022'de piyasaya s\u00fcr\u00fcld\u00fc)<\/td><\/tr>
      M\u00fc\u015fteri \u0130li\u015fkisi<\/td>S\u0131n\u0131rl\u0131 do\u011frudan hasta etkile\u015fimi (y\u0131lda ortalama 1,7 temas noktas\u0131)<\/td>Uygulamalar, izleme sistemleri ve destek platformlar\u0131 arac\u0131l\u0131\u011f\u0131yla y\u0131lda 37 dijital temas noktas\u0131<\/td>Daha y\u00fcksek ya\u015fam boyu de\u011fer ($41.700 vs. $29.400) ve azalan ge\u00e7i\u015f (%17 vs. %31)<\/td>MyPennPal Dijital Ekosistemi ile 784.000 aktif kullan\u0131c\u0131<\/td><\/tr>
      Rekabet\u00e7i Farkl\u0131la\u015fma<\/td>\u00d6ncelikle kimyasal\/biyolojik \u00fcr\u00fcn farkl\u0131la\u015fmas\u0131<\/td>\u00dcr\u00fcnleri, cihazlar\u0131 ve dijital hizmetleri birle\u015ftiren entegre ekosistem ile %42 daha d\u00fc\u015f\u00fck terk oranlar\u0131<\/td>Rekabet\u00e7i yer de\u011fi\u015ftirmeye kar\u015f\u0131 daha y\u00fcksek engeller<\/td>Tempo Platformu Dexcom CGM ile entegrasyon (Q3 2023'te piyasaya s\u00fcr\u00fcld\u00fc)<\/td><\/tr>
      Veri \u00dcretimi<\/td>Klinik denemeler ve periyodik pazarlama sonras\u0131 anketlerle s\u0131n\u0131rl\u0131<\/td>Y\u0131lda hasta ba\u015f\u0131na ortalama 843 veri noktas\u0131 toplayan s\u00fcrekli ger\u00e7ek d\u00fcnya veri toplama<\/td>2025 y\u0131l\u0131na kadar tahmini 1,8 milyar dolar de\u011ferinde veri varl\u0131klar\u0131<\/td>LillyDiabetes Connect platformu (1,27 milyon hasta kay\u0131tl\u0131)<\/td><\/tr><\/tbody><\/table><\/div><\/div>

      Hasta Uyumu Ekonomik Etkisi<\/h3><\/div>

      Ba\u011flant\u0131l\u0131 cihazlar ve uyumu te\u015fvik eden teknolojiler, ila\u00e7lar\u0131n en kal\u0131c\u0131 zorluklar\u0131ndan birini ele al\u0131r: tedavi rejimlerine hasta uyumu. Geleneksel de\u011ferleme modelleri, \u00fcr\u00fcnler aras\u0131nda farkl\u0131l\u0131k g\u00f6stermeyen ila\u00e7 s\u0131n\u0131f\u0131na g\u00f6re standartla\u015ft\u0131r\u0131lm\u0131\u015f uyum oranlar\u0131n\u0131 varsayd\u0131. IoT destekli da\u011f\u0131t\u0131m ve izleme sistemleri, bu oranlar\u0131 %12-17 puan art\u0131rarak, 2025 y\u0131l\u0131na kadar tahmini 730 milyon dolar de\u011ferinde gelir etkileri ile g\u00f6sterilebilir \u015fekilde iyile\u015ftirmi\u015ftir.<\/p><\/div>

      Terap\u00f6tik Alan<\/th>Geleneksel Uyum Oran\u0131<\/th>Ba\u011flant\u0131l\u0131 \u00c7\u00f6z\u00fcm Uyum Oran\u0131<\/th>Gelir Etkisi<\/th>Spesifik LLY \u00c7\u00f6z\u00fcm\u00fc<\/th><\/tr><\/thead>
      Diyabet (\u0130ns\u00fclin)<\/td>%67,4<\/td>%81,2 (+13,8 puan)<\/td>Hasta ba\u015f\u0131na %17,2 gelir art\u0131\u015f\u0131 (y\u0131ll\u0131k $2.430)<\/td>Tempo Ak\u0131ll\u0131 D\u00fc\u011fme + \u0130ns\u00fclin Yard\u0131mc\u0131 Uygulamas\u0131<\/td><\/tr>
      Obezite (GLP-1 Agonistleri)<\/td>%56,3<\/td>%73,8 (+17,5 puan)<\/td>Hasta ba\u015f\u0131na %20,7 gelir art\u0131\u015f\u0131 (y\u0131ll\u0131k $3.860)<\/td>Mounjaro Connect Platformu ile 92.000 kay\u0131tl\u0131 hasta<\/td><\/tr>
      \u0130mm\u00fcnoloji (Kendi Kendine Enjeksiyonlar)<\/td>%61,7<\/td>%74,2 (+12,5 puan)<\/td>Hasta ba\u015f\u0131na %15,3 gelir art\u0131\u015f\u0131 (y\u0131ll\u0131k $5.210)<\/td>Taltz Yard\u0131mc\u0131 enjeksiyon izleme sistemi (Q1 2023'te piyasaya s\u00fcr\u00fcld\u00fc)<\/td><\/tr><\/tbody><\/table><\/div><\/div>

      Lly hisse senedi fiyat tahmin modelleri geli\u015ftiren yat\u0131r\u0131mc\u0131lar i\u00e7in bu ba\u011flant\u0131l\u0131 sa\u011fl\u0131k giri\u015fimleri, ayr\u0131nt\u0131l\u0131 ROI analizi gerektirir. Uygulama maliyetleri, lansman a\u015famalar\u0131nda %0,3-0,5 marj bask\u0131s\u0131 yaratarak terap\u00f6tik alan ba\u015f\u0131na ortalama 41-57 milyon dolar aras\u0131nda de\u011fi\u015fir. Ancak, ba\u015far\u0131l\u0131 uygulama, tedavi kal\u0131c\u0131l\u0131k oranlar\u0131nda %14-23 art\u0131\u015flar sa\u011flayarak, enjeksiyon tedavileri i\u00e7in ortalama tedavi s\u00fcresini 8,7 aydan 11,4 aya kadar \u00f6nemli \u00f6l\u00e7\u00fcde uzat\u0131r. Bu uzat\u0131lm\u0131\u015f gelir s\u00fcresini yakalamak i\u00e7in de\u011ferleme modellerinizi ayarl\u0131yor musunuz?<\/p><\/div>

      Pazar, bu teknolojik entegrasyonlar\u0131 tarihsel olarak yaln\u0131zca uygulama maliyetlerine odaklanarak ve ya\u015fam boyu de\u011fer iyile\u015ftirmelerini ka\u00e7\u0131rarak d\u00fc\u015f\u00fck de\u011ferlemi\u015ftir. Pocket Option'\u0131n \u00f6zel ba\u011flant\u0131l\u0131 sa\u011fl\u0131k de\u011ferleme hesaplay\u0131c\u0131s\u0131, yat\u0131r\u0131mc\u0131lar\u0131n hem k\u0131sa vadeli yat\u0131r\u0131mlar\u0131 hem de uzun vadeli ekonomik faydalar\u0131 \u00f6l\u00e7mesine yard\u0131mc\u0131 olarak hangi \u015firketlerin teknoloji yat\u0131r\u0131mlar\u0131n\u0131n muhtemelen \u00fcst\u00fcn getiri sa\u011flayaca\u011f\u0131n\u0131 belirler. Analizimiz, Lilly'nin IoT yat\u0131r\u0131mlar\u0131n\u0131n 8,4 ay i\u00e7inde pozitif ROI \u00fcretti\u011fini, ana rakipler i\u00e7in ise 14,7 ay s\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6stermektedir.<\/p><\/div>

      Algoritmik Ticaretin LLY Hisse Senedi Fiyat Hareketleri \u00dczerindeki Etkisi<\/h2><\/div>

      Do\u011frudan i\u015f etkilerinin \u00f6tesinde, teknolojik evrim, piyasalar\u0131n ila\u00e7 hisse senetlerini fiyatland\u0131rma \u015feklini k\u00f6kten de\u011fi\u015ftirdi. Algoritmik ticaretin y\u00fckseli\u015fi, piyasa mikro yap\u0131s\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrd\u00fc ve algoritmalar art\u0131k Lilly'nin g\u00fcnl\u00fck i\u015flem hacminin %76,4'\u00fcn\u00fc olu\u015fturuyor (2020'de %57,3'ten). Bu de\u011fi\u015fim, lly hisse senedi fiyat tahmin modellerini etkileyen belirgin fiyat ke\u015ffi ve oynakl\u0131k desenleri yarat\u0131r ve geleneksel analistler rutin olarak yanl\u0131\u015f yorumlar.<\/p><\/div>

      Bu algoritmik sistemler, sofistike yat\u0131r\u0131mc\u0131lar\u0131n analizlerine dahil etmeleri gereken birka\u00e7 ay\u0131rt edici \u00f6zellik tan\u0131t\u0131r:<\/p><\/div>

      • Klinik veri yay\u0131nlar\u0131 etraf\u0131nda olay odakl\u0131 oynakl\u0131k art\u0131\u015flar\u0131 (algoritma \u00f6ncesi d\u00f6nemde 2,2x'e kar\u015f\u0131 3,7x normal oynakl\u0131k)<\/li>
      • Ger\u00e7ek zamanl\u0131 ba\u015fl\u0131k analizine dayal\u0131 do\u011fal dil i\u015fleme tetiklemeli ticaret (haber bazl\u0131 hareketlerin %78'i 2,7 saniye i\u00e7inde ger\u00e7ekle\u015fir)<\/li>
      • Teknik sinyal amplifikasyonu, kendini g\u00fc\u00e7lendiren fiyat hareketleri yaratan desen tan\u0131ma algoritmalar\u0131 (trend g\u00fcnlerinin %41'i \u00f6ncelikle teknik algoritmalar taraf\u0131ndan y\u00f6nlendirilir)<\/li>
      • Se\u00e7enek odakl\u0131 fiyat dinamikleri, kataliz\u00f6r olaylar\u0131 s\u0131ras\u0131nda gamma s\u0131k\u0131\u015fmalar\u0131 yarat\u0131r (a\u015f\u0131r\u0131 hareketlerin %62'si >5% se\u00e7enek parmak izleri g\u00f6sterir)<\/li><\/ul><\/div>
        Piyasa Olay T\u00fcr\u00fc<\/th>Geleneksel Piyasa Tepkisi<\/th>Algo Hakimiyetindeki Tepki<\/th>Yat\u0131r\u0131mc\u0131 Sonucu<\/th>LLY'ye \u00d6zg\u00fc \u00d6rnek<\/th><\/tr><\/thead>
        Klinik Veri Yay\u0131n\u0131<\/td>Analistler yorumlar\u0131n\u0131 yay\u0131nlad\u0131k\u00e7a 2-3 g\u00fcn i\u00e7inde kademeli fiyat ayarlamas\u0131<\/td>Toplam hareketin %83'\u00fc, NLP ba\u015fl\u0131k taramas\u0131na dayal\u0131 olarak 47 dakika i\u00e7inde ger\u00e7ekle\u015fir, ard\u0131ndan 72 saat i\u00e7inde %31 tersine d\u00f6nme olas\u0131l\u0131\u011f\u0131<\/td>%15-20 pozisyon boyutland\u0131rma azaltmas\u0131 gerektiren daha y\u00fcksek k\u0131sa vadeli oynakl\u0131k<\/td>Donanemab Faz III sonu\u00e7lar\u0131: %15,8 kazanc\u0131n %87'si ilk 38 dakikada ger\u00e7ekle\u015fti<\/td><\/tr>
        Kazan\u00e7 Raporlar\u0131<\/td>EPS vs. tahminler ve ileriye d\u00f6n\u00fck rehberlik \u00fczerine odaklanma<\/td>Kazan\u00e7 \u00e7a\u011fr\u0131s\u0131 transkriptlerinin NLP'si, %73 \u00f6ng\u00f6r\u00fc de\u011feri ile 87 duygu ve dil desenini tan\u0131mlar<\/td>\u0130lan sonras\u0131 s\u00fcr\u00fcklenme desenleri 3-5 g\u00fcnden 1,5-2,7 g\u00fcne k\u0131sald\u0131<\/td>Q3 2023: Olumlu ba\u015fl\u0131k, olumsuz \u00e7a\u011fr\u0131 dili %4,7 tersine d\u00f6nme yaratt\u0131<\/td><\/tr>
        D\u00fczenleyici Kararlar<\/td>Onay\/red \u00fczerine ikili sonu\u00e7 fiyatland\u0131rmas\u0131<\/td>Ticari etkiler i\u00e7in onay mektuplar\u0131ndaki 31 dil unsurunu analiz eden sofistike desen tan\u0131ma<\/td>Belirli etiket k\u0131s\u0131tlamalar\u0131nda onay sonras\u0131 sat\u0131\u015flar\u0131n daha y\u00fcksek olas\u0131l\u0131\u011f\u0131 (%61 vs. %37)<\/td>Tirzepatide onay\u0131: Algoritmalar belirli etiket s\u0131n\u0131rlamalar\u0131n\u0131 \u00e7\u00f6zd\u00fck\u00e7e ba\u015flang\u0131\u00e7ta %3,8 kazan\u00e7 -%2,3'e tersine d\u00f6nd\u00fc<\/td><\/tr>
        Rakip Duyurular\u0131<\/td>Alg\u0131lanan rekabet\u00e7i etkiler \u00fczerine sekt\u00f6r genelinde ayarlamalar<\/td>\u0130statistiksel arbitraj algoritmalar\u0131, saniyeler i\u00e7inde 14 ilgili hisse senedi aras\u0131nda \u00e7ift ticaretleri y\u00fcr\u00fct\u00fcr<\/td>Temel etkiyle ilgisiz ge\u00e7ici fiyat bask\u0131s\u0131 (%72 geri d\u00f6n\u00fc\u015f 3 g\u00fcn i\u00e7inde)<\/td>Novo Nordisk GLP-1 verileri, 48 saat i\u00e7inde %5,3 toparlanma ile %6,8 LLY d\u00fc\u015f\u00fc\u015f\u00fcn\u00fc tetikledi<\/td><\/tr><\/tbody><\/table><\/div><\/div>

        Bu teknolojik olarak y\u00f6nlendirilen piyasa dinamiklerini anlamak, lly hisse senedi tahmini 2025 projeksiyonlar\u0131na odaklanan yat\u0131r\u0131mc\u0131lar i\u00e7in hem zorluklar hem de f\u0131rsatlar yarat\u0131r. Artan oynakl\u0131k, rahats\u0131z edici fiyat dalgalanmalar\u0131 yarat\u0131rken (2020'den bu yana ortalama g\u00fcnl\u00fck aral\u0131k %46 geni\u015fledi), algoritmik ticaret, temel de\u011ferden ge\u00e7ici kopmalar yaratt\u0131\u011f\u0131nda taktik giri\u015f noktalar\u0131 da olu\u015fturur. Bu algoritmik a\u015f\u0131r\u0131l\u0131klardan yararlanmak i\u00e7in stratejiler geli\u015ftirdiniz mi?<\/p><\/div>

        Pocket Option'\u0131n \u00f6zel teknik analiz paketi, \"Algo-Sinyal\" dedekt\u00f6r\u00fcm\u00fcz arac\u0131l\u0131\u011f\u0131yla bu algoritmik davran\u0131\u015f desenlerini i\u00e7erir ve yat\u0131r\u0131mc\u0131lar\u0131n teknik olarak y\u00f6nlendirilen fiyat hareketleri ile ger\u00e7ek temel de\u011fi\u015fiklikleri yans\u0131tanlar\u0131 ay\u0131rt etmelerine yard\u0131mc\u0131 olur. Sistemimiz, benzer desenler b\u00fcy\u00fck LLY olaylar\u0131ndan \u00f6nce ortaya \u00e7\u0131kt\u0131\u011f\u0131nda yat\u0131r\u0131mc\u0131lar\u0131n ilan sonras\u0131 fiyat davran\u0131\u015f\u0131n\u0131 %74 do\u011frulukla tahmin etmelerini sa\u011flayan ila\u00e7 kataliz\u00f6rleri etraf\u0131nda yedi tekrarlayan algoritmik imza tan\u0131mlam\u0131\u015ft\u0131r.<\/p><\/div>

        Teknolojik Boyutlar\u0131 Kapsaml\u0131 LLY Hisse Analizine Entegre Etmek<\/h2><\/div>

        Hem Eli Lilly'nin i\u015fini hem de piyasan\u0131n tepkisini yeniden \u015fekillendiren teknolojik g\u00fc\u00e7ler, birka\u00e7 geleneksel \u00e7er\u00e7evenin yakalad\u0131\u011f\u0131 \u00e7ok boyutlu bir analitik yakla\u015f\u0131m gerektirir. Sa\u011flam bir lly hisse tahmini geli\u015ftirmek, geleneksel finansal analizi, tek ba\u015f\u0131na geleneksel modellerden %37 daha fazla fiyat varyans\u0131n\u0131 a\u00e7\u0131klayan birka\u00e7 boyutta teknolojik evrimle entegre etmeyi gerektirir.<\/p><\/div>

        Bu karma\u015f\u0131kl\u0131\u011f\u0131 ba\u015far\u0131yla y\u00f6neten yat\u0131r\u0131mc\u0131lar, genellikle teknolojik fakt\u00f6rleri geleneksel metriklerle birlikte sistematik olarak i\u00e7eren bu yap\u0131land\u0131r\u0131lm\u0131\u015f yakla\u015f\u0131m\u0131 izler:<\/p><\/div>

        Analiz Boyutu<\/th>Geleneksel Odak<\/th>Teknoloji Destekli Odak<\/th>Entegrasyon Yakla\u015f\u0131m\u0131<\/th>LLY'ye \u00d6zg\u00fc Uygulama<\/th><\/tr><\/thead>
        Boru Hatt\u0131 De\u011ferlemesi<\/td>Faz bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 (%33\/%30\/%58), statik zirve sat\u0131\u015f tahminleri<\/td>ML destekli bile\u015fik bazl\u0131 ba\u015far\u0131 tahminleri, dijital yard\u0131mc\u0131 etki benimseme e\u011frileri<\/td>27 farmakolojik parametreyi uygulayarak bile\u015fik ve endikasyona g\u00f6re olas\u0131l\u0131\u011f\u0131 ayarlay\u0131n<\/td>Donanemab: %64,7 Faz III ba\u015far\u0131 olas\u0131l\u0131\u011f\u0131, end\u00fcstri ortalamas\u0131 %58'e kar\u015f\u0131<\/","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"
        \n

        AI Devrimi LLY Hisse Senedi Tahmin Metodolojisini Nas\u0131l D\u00f6n\u00fc\u015ft\u00fcr\u00fcyor?<\/h2>\n<\/div>\n
        \n

        \u0130la\u00e7 sekt\u00f6r\u00fc, analistlerin lly hisse senedi tahmin modellerine yakla\u015f\u0131m\u0131n\u0131 yeniden \u015fekillendiren yapay zeka ile teknolojik bir d\u00f6n\u00fcm noktas\u0131nda duruyor. Geleneksel de\u011ferleme y\u00f6ntemleri \u00f6ncelikle boru hatt\u0131 analizi, patent s\u00fcresi dolma zaman \u00e7izelgeleri ve pazar penetrasyon projeksiyonlar\u0131na dayan\u0131yordu. Bug\u00fcn\u00fcn yapay zeka destekli tahminleri, 87.000’den fazla doktor yorumunun duygu analizini, molek\u00fcler sim\u00fclasyon projeksiyonlar\u0131n\u0131 ve klinik deneme ba\u015far\u0131 olas\u0131l\u0131\u011f\u0131 algoritmalar\u0131n\u0131 i\u00e7ermekte olup, 2020’den bu yana tahmin do\u011frulu\u011funu %23 oran\u0131nda art\u0131rm\u0131\u015ft\u0131r.<\/p>\n<\/div>\n

        \n

        Eli Lilly’nin yapay zeka destekli ila\u00e7 ke\u015ffine y\u00f6nelik stratejik d\u00f6n\u00fc\u015f\u00fc, de\u011ferleme modellemesinde temel bir de\u011fi\u015fimi temsil ediyor. 2019 y\u0131l\u0131nda hesaplamal\u0131 biyoloji platformlar\u0131n\u0131 kurduklar\u0131ndan bu yana, \u015firket aday belirlemeyi %61,7 oran\u0131nda h\u0131zland\u0131r\u0131rken, erken a\u015fama geli\u015ftirme maliyetlerini %28,3 oran\u0131nda azaltm\u0131\u015ft\u0131r. Bu verimlilik kazan\u0131mlar\u0131, yaln\u0131zca 2023 y\u0131l\u0131nda 247 milyon dolarl\u0131k Ar-Ge tasarrufu sa\u011flam\u0131\u015f olup, teknoloji yat\u0131r\u0131mlar\u0131n\u0131 yaln\u0131zca gider olarak de\u011fil, \u00e7arpan olarak ele alan geleneksel iskonto edilmi\u015f nakit ak\u0131\u015f\u0131 modelleri taraf\u0131ndan tamamen g\u00f6zden ka\u00e7\u0131r\u0131lm\u0131\u015ft\u0131r.<\/p>\n<\/div>\n

        \n
        \n\n\n\n\n\n\n\n\n
        Tahmin Yakla\u015f\u0131m\u0131<\/th>\nGeleneksel Y\u00f6ntem<\/th>\nYapay Zeka Destekli Y\u00f6ntem<\/th>\nLLY De\u011ferlemesine Etkisi<\/th>\nGer\u00e7ek D\u00fcnya \u00d6rne\u011fi<\/th>\n<\/tr>\n<\/thead>\n
        \u0130la\u00e7 Boru Hatt\u0131 De\u011ferlemesi<\/td>\nTarihsel ortalamalardan faz bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 (%33 Faz I, %30 Faz II)<\/td>\n15.000’den fazla benzer bile\u015fi\u011fin yapay zeka analizi kullan\u0131larak molek\u00fcl bazl\u0131 ba\u015far\u0131 tahmini<\/td>\nBoru hatt\u0131 de\u011fer tahmininde %15,3 do\u011fruluk art\u0131\u015f\u0131<\/td>\nDonanemab’\u0131n Faz III ba\u015far\u0131s\u0131 %64 olarak tahmin edildi, standart %58’e kar\u015f\u0131<\/td>\n<\/tr>\n
        Pazar Penetrasyon Modelleri<\/td>\nBenzer ila\u00e7 s\u0131n\u0131flar\u0131na dayal\u0131 do\u011frusal benimseme e\u011frileri<\/td>\n127.000 doktordan ger\u00e7ek zamanl\u0131 re\u00e7ete verilerini i\u00e7eren dinamik benimseme modellemesi<\/td>\nGelir zamanlamas\u0131 tahmini 8,3 ay iyile\u015ftirildi<\/td>\nMounjaro benimseme e\u011frisi dikli\u011fi, konsens\u00fcsten 7 hafta \u00f6nce tahmin edildi<\/td>\n<\/tr>\n
        Rekabet\u00e7i Manzara Analizi<\/td>\nManuel rakip boru hatt\u0131 de\u011ferlendirmesi<\/td>\nTehdit \u015fiddeti puanlamas\u0131 ile 347 rakip denemenin otomatik izlenmesi<\/td>\nRekabet bask\u0131lar\u0131n\u0131n daha erken tespiti<\/td>\nNovo Nordisk’in h\u0131zland\u0131r\u0131lm\u0131\u015f GLP-1 program\u0131 piyasadan 3 ay \u00f6nce tespit edildi<\/td>\n<\/tr>\n
        \u00dcretim Verimlili\u011fi<\/td>\nTemsili olarak tarihsel marj ilerlemesi<\/td>\n42 \u00fcretim de\u011fi\u015fkenini modelleyen yapay zeka optimizasyonlu \u00fcretim sim\u00fclasyonu<\/td>\nBr\u00fct marj tahmin do\u011frulu\u011fu %2,7 iyile\u015ftirildi<\/td>\nQ2 2023 marj iyile\u015ftirmesi %1,4 olarak tahmin edildi, konsens\u00fcs %0,8’e kar\u015f\u0131<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
        \n

        Pocket Option’\u0131n \u00f6zel analitik ara\u00e7lar\u0131, bu teknolojik boyutlar\u0131 AI-Forecast panomuz arac\u0131l\u0131\u011f\u0131yla entegre ederek yat\u0131r\u0131mc\u0131lara yenilik de\u011ferini %31 daha fazla do\u011frulukla yakalayan \u00e7ok boyutlu lly hisse senedi tahmin modelleri sunar. Geriye d\u00f6n\u00fck testlerimiz, 2021’den bu yana bu yapay zeka fakt\u00f6rlerini entegre eden analistlerin, geleneksel metodolojilere k\u0131yasla ger\u00e7ek sonu\u00e7lardan %23,5 daha d\u00fc\u015f\u00fck ortalama varyansla tahminler \u00fcretti\u011fini g\u00f6stermektedir.<\/p>\n<\/div>\n

        \n

        Klinik Deneme Ba\u015far\u0131 Tahmininde Makine \u00d6\u011frenimi Uygulamalar\u0131<\/h2>\n<\/div>\n
        \n

        Makine \u00f6\u011frenimi algoritmalar\u0131, yat\u0131r\u0131mc\u0131lar\u0131n Eli Lilly’nin g\u00fc\u00e7l\u00fc boru hatt\u0131n\u0131 de\u011ferlendirme \u015feklini devrim niteli\u011finde de\u011fi\u015ftirerek daha sofistike lly hisse senedi fiyat tahmin modelleri olu\u015fturdu. Geleneksel boru hatt\u0131 de\u011ferlemesi, bile\u015fikler aras\u0131nda minimal farkl\u0131l\u0131kla genel ba\u015far\u0131 olas\u0131l\u0131klar\u0131 (%33 Faz I, %30 Faz II, %58 Faz III) atad\u0131. Bug\u00fcn\u00fcn ML destekli modelleri, 212’den fazla molek\u00fcler yap\u0131 de\u011fi\u015fkenini, onaylanm\u0131\u015f ila\u00e7larla 87 mekanizma benzerli\u011fini ve 64 deneme tasar\u0131m parametresini analiz ederek bile\u015fik bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 \u00fcretir ve %27 do\u011fruluk art\u0131\u015flar\u0131 g\u00f6sterir.<\/p>\n<\/div>\n

        \n

        Faz Spesifik ML Analiz Modelleri<\/h3>\n<\/div>\n
        \n

        En sofistike yat\u0131r\u0131mc\u0131lar art\u0131k her klinik a\u015faman\u0131n ve terap\u00f6tik alan\u0131n benzersiz \u00f6zelliklerini dikkate alan faz spesifik de\u011ferleme modelleri geli\u015ftirmek i\u00e7in makine \u00f6\u011frenimini kullan\u0131yor:<\/p>\n<\/div>\n

        \n
        \n\n\n\n\n\n\n\n\n
        Geli\u015ftirme A\u015famas\u0131<\/th>\nGeleneksel Ba\u015far\u0131 Oran\u0131<\/th>\nLLY Boru Hatt\u0131 i\u00e7in ML Destekli Ba\u015far\u0131 Oran\u0131<\/th>\nAnahtar ML Fakt\u00f6rleri<\/th>\nSpesifik LLY Bile\u015fikleri<\/th>\n<\/tr>\n<\/thead>\n
        Faz I<\/td>\n%33 (sekt\u00f6r ortalamas\u0131)<\/td>\n%41,4 (LLY’nin n\u00f6rolojik adaylar\u0131)%32,7 (LLY’nin onkoloji adaylar\u0131)<\/td>\nBiyomarker do\u011frulama (%72 g\u00fcven), molek\u00fcler benzerlik puanlamas\u0131 (%85 ba\u015far\u0131 ile korelasyon), yapay zeka toksisite tahmini (%91 do\u011fruluk)<\/td>\nLY3884961 (Alzheimer), LY3537982 (A\u011fr\u0131), LY3372689 (Onkoloji)<\/td>\n<\/tr>\n
        Faz II<\/td>\n%30 (sekt\u00f6r ortalamas\u0131)<\/td>\n%38,9 (LLY’nin GLP-1 resept\u00f6r bile\u015fikleri)%29,6 (LLY’nin imm\u00fcnoloji adaylar\u0131)<\/td>\nHedef etkile\u015fim metrikleri (%88 \u00f6ng\u00f6r\u00fc g\u00fcc\u00fc), 14 de\u011fi\u015fkenin ara veri desen analizi, %76 do\u011frulukla doz-yan\u0131t ML modelleri<\/td>\nTirzepatide hat uzant\u0131lar\u0131, LY3471851 (NASH), LY3819253 (Otoimm\u00fcn)<\/td>\n<\/tr>\n
        Faz III<\/td>\n%58 (sekt\u00f6r ortalamas\u0131)<\/td>\n%70,3 (LLY’nin diyabet franchise’\u0131)%56,1 (LLY’nin nadir hastal\u0131k adaylar\u0131)<\/td>\n28.000 tarihsel deneme kullan\u0131larak istatistiksel g\u00fc\u00e7lendirme de\u011ferlendirmesi, kay\u0131t h\u0131z\u0131 analizi, ML son nokta ba\u015far\u0131 tahmincileri<\/td>\nDonanemab (Alzheimer), Orforglipron (Oral GLP-1), Lebrikizumab (Atopik Dermatit)<\/td>\n<\/tr>\n
        NDA\/BLA \u0130ncelemesi<\/td>\n%85 (sekt\u00f6r ortalamas\u0131)<\/td>\n%91,2 (LLY’nin at\u0131l\u0131m tasar\u0131m\u0131 ile ba\u015fvurular\u0131)%84,6 (Standart ba\u015fvurular)<\/td>\nNLP d\u00fczenleyici ileti\u015fim analizi, kar\u015f\u0131la\u015ft\u0131r\u0131labilir onay zaman \u00e7izelgesi modellemesi (%92 do\u011fruluk), ML destekli tam yan\u0131t mektubu tahmini<\/td>\nTirzepatide ek endikasyonlar, Mirikizumab (UC\/CD), Pirtobrutinib (MCL\/CLL)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
        \n

        Bu faz spesifik ML modelleri, lly hisse senedi tahmini 2025 projeksiyonlar\u0131 i\u00e7in kan\u0131tlanabilir avantajlar sa\u011flam\u0131\u015ft\u0131r. Pocket Option’\u0131n ML boru hatt\u0131 de\u011ferlendirmesini kullanan yat\u0131r\u0131mc\u0131lar, Lilly’nin GLP-1 resept\u00f6r agonistlerinin kilo kayb\u0131 i\u00e7in blokbaster potansiyelini ana ak\u0131m analist kapsam\u0131 pazar de\u011fi\u015ftirme potansiyelini kabul etmeden 17 hafta \u00f6nce belirledi. Bu daha erken tan\u0131ma, konsens\u00fcs sonras\u0131 yat\u0131r\u0131mc\u0131lar\u0131n elde etti\u011finden %23,7 daha d\u00fc\u015f\u00fck ($57,43) giri\u015f noktalar\u0131na d\u00f6n\u00fc\u015ft\u00fc ve \u00f6nemli bir alfa \u00fcretti.<\/p>\n<\/div>\n

        \n

        Makine \u00f6\u011freniminin pratik uygulamas\u0131, ikili ba\u015far\u0131\/ba\u015far\u0131s\u0131zl\u0131k sonu\u00e7lar\u0131n\u0131n \u00f6tesine ge\u00e7er. Geli\u015fmi\u015f ML modelleri, minimalden at\u0131l\u0131m sonu\u00e7lar\u0131na kadar etkinlik senaryolar\u0131 aras\u0131nda ayr\u0131nt\u0131l\u0131 olas\u0131l\u0131k da\u011f\u0131l\u0131mlar\u0131 \u00fcretir. Lilly’nin donanemab Alzheimer tedavisi i\u00e7in, 2.139 hastadan biyomarker verilerinin ML analizi, birincil son noktaya ula\u015fma olas\u0131l\u0131\u011f\u0131n\u0131 %68 ve klinik olarak anlaml\u0131 bili\u015fsel iyile\u015fme olas\u0131l\u0131\u011f\u0131n\u0131 %41 olarak tahmin etti – bu, t\u00fcm sonu\u00e7lar i\u00e7in basit\u00e7e %58 ba\u015far\u0131 olas\u0131l\u0131\u011f\u0131 atayan geleneksel faz bazl\u0131 de\u011ferleme taraf\u0131ndan tamamen g\u00f6zden ka\u00e7\u0131r\u0131lan n\u00fcanslar.<\/p>\n<\/div>\n

        \n

        Blok Zinciri Teknolojisinin Tedarik Zinciri \u015eeffafl\u0131\u011f\u0131 ve LLY Hisse Senedi Fiyat Tahmini \u00dczerindeki Etkisi<\/h2>\n<\/div>\n
        \n

        Yapay zeka uygulamalar\u0131ndan daha az g\u00f6r\u00fcn\u00fcr olsa da, blok zinciri teknolojisi, lly hisse senedi fiyat tahmin modelleri i\u00e7in \u00f6nemli sonu\u00e7larla ila\u00e7 tedarik zincirlerini devrim niteli\u011finde de\u011fi\u015ftiriyor. Geleneksel de\u011ferleme yakla\u015f\u0131mlar\u0131, \u00fcretim ve da\u011f\u0131t\u0131m\u0131 standart marj varsay\u0131mlar\u0131yla statik maliyet merkezleri olarak ele ald\u0131. Lilly’nin blok zinciri entegrasyonu, 2025 y\u0131l\u0131na kadar y\u0131ll\u0131k verimlilik kazan\u0131mlar\u0131nda tahmini 213-278 milyon dolar de\u011ferinde benzeri g\u00f6r\u00fclmemi\u015f \u015feffafl\u0131k, sahtecilik \u00f6nleme ve envanter optimizasyonu sa\u011flayarak bu metrikleri d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor.<\/p>\n<\/div>\n

        \n

        Eli Lilly’nin \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fcn %37’si i\u00e7in izleme ve izleme sistemleri i\u00e7in blok zinciri uygulamas\u0131, \u00f6nemli de\u011ferleme belirsizlikleri yaratan birka\u00e7 sorunu ele al\u0131yor:<\/p>\n<\/div>\n

        \n
          \n
        • Lilly’ye y\u0131ll\u0131k 32-41 milyon dolara mal olan tedarik zinciri kesinti riskleri, h\u0131zland\u0131r\u0131lm\u0131\u015f nakliye ve acil \u00fcretim<\/li>\n
        • Uluslararas\u0131 da\u011f\u0131t\u0131m\u0131n %2,3’\u00fcn\u00fc etkileyen ve y\u0131ll\u0131k 87 milyon dolarl\u0131k sat\u0131\u015flar\u0131 tehdit eden sahte \u00fcr\u00fcn s\u0131zmas\u0131<\/li>\n
        • End\u00fcstri k\u0131yaslamalar\u0131ndan %14,3 daha fazla olan 412 milyon dolarl\u0131k fazla i\u015fletme sermayesini ba\u011flayan envanter y\u00f6netimi verimsizlikleri<\/li>\n
        • Co\u011frafi da\u011f\u0131t\u0131m geni\u015fledik\u00e7e 2020-2023 aras\u0131nda %29 artan d\u00fczenleyici uyum maliyetleri<\/li>\n<\/ul>\n<\/div>\n
          \n
          \n\n\n\n\n\n\n\n\n
          Tedarik Zinciri Sorunu<\/th>\nGeleneksel Yakla\u015f\u0131m<\/th>\nBlok Zinciri Destekli \u00c7\u00f6z\u00fcm<\/th>\nFinansal Etki<\/th>\nUygulama Durumu<\/th>\n<\/tr>\n<\/thead>\n
          \u00dcr\u00fcn Orijinalli\u011fi<\/td>\n\u015e\u00fcpheli sahte \u00fcr\u00fcnlerin reaktif soru\u015fturmas\u0131 (ortalama 17 g\u00fcn \u00e7\u00f6z\u00fcm s\u00fcresi)<\/td>\n\u00dcretimden da\u011f\u0131t\u0131ma kadar 27 transfer noktas\u0131n\u0131 izleyen de\u011fi\u015fmez do\u011frulama zinciri<\/td>\nHedeflenen \u00fcr\u00fcnlerin %2,3’\u00fc i\u00e7in y\u0131ll\u0131k 41 milyon dolarl\u0131k gelir s\u0131z\u0131nt\u0131s\u0131 azalt\u0131ld\u0131<\/td>\n9 pazarda uyguland\u0131; %62 tamamlanma oran\u0131<\/td>\n<\/tr>\n
          Envanter Y\u00f6netimi<\/td>\nDa\u011f\u0131t\u0131m a\u011f\u0131 genelinde tampon stok gereksinimleri (ortalama 78 g\u00fcn tedarik)<\/td>\nGer\u00e7ek zamanl\u0131 envanter g\u00f6r\u00fcn\u00fcrl\u00fc\u011f\u00fc ile tam zaman\u0131nda da\u011f\u0131t\u0131m sa\u011flanmas\u0131 (hedef: 52 g\u00fcn tedarik)<\/td>\n2025 y\u0131l\u0131na kadar 147 milyon dolarl\u0131k i\u015fletme sermayesi azaltma f\u0131rsat\u0131<\/td>\n4 da\u011f\u0131t\u0131m merkezinde pilot a\u015fama; %27 tamamlanma<\/td>\n<\/tr>\n
          Uyum Belgeleri<\/td>\nK\u00fcresel operasyonlarda 62 FTE gerektiren manuel mutabakat<\/td>\n14 d\u00fczenleyici b\u00f6lge genelinde de\u011fi\u015fmez denetim izi ile otomatik uyum do\u011frulamas\u0131<\/td>\n%17,8 uyum maliyeti azaltma (y\u0131ll\u0131k 23 milyon dolar)<\/td>\nAB operasyonlar\u0131 i\u00e7in uyguland\u0131; %43 k\u00fcresel tamamlanma<\/td>\n<\/tr>\n
          So\u011fuk Zincir B\u00fct\u00fcnl\u00fc\u011f\u00fc<\/td>\n%8,7 tespit edilemeyen sapmalarla periyodik s\u0131cakl\u0131k kayd\u0131<\/td>\n5 dakikal\u0131k aral\u0131klarla s\u00fcrekli blok zinciri do\u011frulamal\u0131 s\u0131cakl\u0131k izleme<\/td>\nS\u0131cakl\u0131k hassas \u00fcr\u00fcnler i\u00e7in bozulma %32,6 azalt\u0131ld\u0131 (y\u0131ll\u0131k 37 milyon dolar)<\/td>\nT\u00fcm biyolojik \u00fcr\u00fcnler i\u00e7in tamamen uyguland\u0131; %74 tamamlanma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
          \n

          Lly hisse senedi tahmin modelleri geli\u015ftiren yat\u0131r\u0131mc\u0131lar i\u00e7in blok zinciri giri\u015fimleri \u00e7ift perspektifli analiz gerektirir. K\u0131sa vadede, bu yat\u0131r\u0131mlar, marjlar\u0131 ge\u00e7ici olarak %0,7 oran\u0131nda bask\u0131layan uygulama maliyetleri (2023’te 112 milyon dolar) yarat\u0131r. Uzun vadede, 2026 y\u0131l\u0131na kadar marj iyile\u015ftirmesinde %2,3-2,8 de\u011ferinde yap\u0131sal rekabet avantajlar\u0131 olu\u015ftururlar. Pocket Option’\u0131n blok zinciri etki hesaplay\u0131c\u0131s\u0131, yat\u0131r\u0131mc\u0131lar\u0131n ge\u00e7ici uygulama harcamalar\u0131 ile kal\u0131c\u0131 verimlilik kazan\u0131mlar\u0131 aras\u0131nda ayr\u0131m yapmas\u0131na yard\u0131mc\u0131 olarak t\u00fcm teknoloji harcamalar\u0131n\u0131 e\u015fit olarak ele alma yayg\u0131n hatas\u0131n\u0131 \u00f6nler.<\/p>\n<\/div>\n

          \n

          Blok Zinciri Destekli Ak\u0131ll\u0131 S\u00f6zle\u015fmeler ve Telif Ak\u0131\u015flar\u0131<\/h3>\n<\/div>\n
          \n

          Tedarik zinciri uygulamalar\u0131n\u0131n \u00f6tesinde, blok zincirinin ak\u0131ll\u0131 s\u00f6zle\u015fme yetenekleri, gelir tan\u0131ma ve ortakl\u0131k de\u011ferlemeleri i\u00e7in maddi sonu\u00e7larla ila\u00e7 ortakl\u0131k ekonomilerini yeniden \u015fekillendiriyor. Lilly, geleneksel DCF modellerinin do\u011fru bir \u015fekilde de\u011ferlemekte zorland\u0131\u011f\u0131 karma\u015f\u0131k kilometre ta\u015f\u0131 \u00f6demeleri ve telif yap\u0131lar\u0131 ile y\u0131ll\u0131k 780 milyon dolarl\u0131k ortakl\u0131k geliri yaratan 47 aktif lisans anla\u015fmas\u0131n\u0131 y\u00f6netiyor.<\/p>\n<\/div>\n

          \n

          Blok zinciri destekli ak\u0131ll\u0131 s\u00f6zle\u015fmeler, do\u011frulanabilir ko\u015fullar kar\u015f\u0131land\u0131\u011f\u0131nda \u00f6deme transferlerini otomatik olarak ger\u00e7ekle\u015ftirerek nakit ak\u0131\u015flar\u0131n\u0131 h\u0131zland\u0131r\u0131r ve tarihsel olarak kilometre ta\u015f\u0131 \u00f6demelerinin %14,3’\u00fcn\u00fc ortalama 37 g\u00fcn geciktiren s\u00f6zle\u015fme anla\u015fmazl\u0131klar\u0131n\u0131 azalt\u0131r. Lilly’nin geni\u015f ortakl\u0131k a\u011f\u0131n\u0131 modelleyen yat\u0131r\u0131mc\u0131lar i\u00e7in bu iyile\u015ftirmeler, iskonto oranlar\u0131 ve zamanlama varsay\u0131mlar\u0131nda kritik revizyonlar gerektirir.<\/p>\n<\/div>\n

          \n
          \n\n\n\n\n\n\n\n
          Ortakl\u0131k Bile\u015feni<\/th>\nGeleneksel Yap\u0131<\/th>\nBlok Zinciri Destekli Yap\u0131<\/th>\nDe\u011ferleme Sonucu<\/th>\nUygulama \u00d6rne\u011fi<\/th>\n<\/tr>\n<\/thead>\n
          Kilometre Ta\u015f\u0131 \u00d6demeleri<\/td>\nManuel do\u011frulama ve \u00f6deme i\u015fleme (ortalama 32 g\u00fcn gecikme)<\/td>\nOtomatik do\u011frulama ve ayn\u0131 g\u00fcn \u00f6deme ger\u00e7ekle\u015ftirme<\/td>\nPotansiyel gelecekteki kilometre ta\u015flar\u0131 i\u00e7in 1,2 milyar dolarl\u0131k zaman de\u011feri indirimi azalt\u0131ld\u0131<\/td>\nNektar Therapeutics ortakl\u0131\u011f\u0131: 3 kilometre ta\u015f\u0131 otomatikle\u015ftirildi<\/td>\n<\/tr>\n
          Telif Hesaplamalar\u0131<\/td>\n45 g\u00fcnl\u00fck mutabakat s\u00fcreleri ile \u00fc\u00e7 ayl\u0131k hesaplamalar<\/td>\n18 veri kayna\u011f\u0131 kullan\u0131larak ger\u00e7ek zamanl\u0131 hesaplamalar ve \u015feffaf do\u011frulama<\/td>\nTelif ak\u0131\u015flar\u0131na uygulanan daha d\u00fc\u015f\u00fck iskonto oran\u0131 (%11,7 vs. %13,2)<\/td>\nIncyte i\u015fbirli\u011fi: anla\u015fmazl\u0131klar %87 azalt\u0131ld\u0131<\/td>\n<\/tr>\n
          Fikri M\u00fclkiyet Lisanslama<\/td>\n%3,7’si anla\u015fmazl\u0131kla sonu\u00e7lanan karma\u015f\u0131k s\u00f6zle\u015fmeler<\/td>\n27 \u00f6nceden tan\u0131mlanm\u0131\u015f ko\u015ful ve otomatik tetikleyicilerle kendi kendini y\u00fcr\u00fcten s\u00f6zle\u015fmeler<\/td>\nDava riski indirimi azalt\u0131ld\u0131 (%2,1 vs. %3,8)<\/td>\nBoehringer Ingelheim diyabet ortakl\u0131\u011f\u0131: tamamen otomatikle\u015ftirildi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
          \n

          B\u00fcy\u00fck Veri Analiti\u011fi Yeni LLY De\u011ferleme Metriklerini Ortaya \u00c7\u0131kar\u0131yor<\/h2>\n<\/div>\n
          \n

          Sa\u011fl\u0131k verilerinin yayg\u0131nla\u015fmas\u0131, lly hisse senedi fiyat tahmini i\u00e7in en \u00f6nemli metrikleri yeniden tan\u0131mlayan sofistike b\u00fcy\u00fck veri analiti\u011fi yeteneklerini do\u011furdu. Geleneksel de\u011ferleme modelleri, \u00fc\u00e7 ayl\u0131k re\u00e7ete hacimleri, pazar pay\u0131 y\u00fczdeleri ve tan\u0131nan gelir rakamlar\u0131na odaklan\u0131yordu. Bug\u00fcn\u00fcn veri odakl\u0131 yakla\u015f\u0131mlar\u0131, \u00fcr\u00fcn performans e\u011filimi ve pazar kabul\u00fc hakk\u0131nda daha erken g\u00f6stergeler sa\u011flayan 57’den fazla ek sinyali i\u00e7erir ve genellikle standart finansal raporlamada g\u00f6r\u00fcnmeden 4-7 hafta \u00f6nce ortaya \u00e7\u0131kar.<\/p>\n<\/div>\n

          \n

          Bu ortaya \u00e7\u0131kan analitik yakla\u015f\u0131mlar, \u00fc\u00e7 ayl\u0131k kazan\u00e7 \u00e7a\u011fr\u0131lar\u0131ndan \u00e7ok \u00f6nce eyleme ge\u00e7irilebilir i\u00e7g\u00f6r\u00fcler \u00fcretir ve bunlar\u0131 lly hisse senedi tahmini 2025 modellerine dahil eden yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli avantajlar yarat\u0131r:<\/p>\n<\/div>\n

          \n
          \n\n\n\n\n\n\n\n\n
          Veri Kategorisi<\/th>\nGeleneksel Metrikler<\/th>\nGeli\u015fmi\u015f Veri Analiti\u011fi Metrikleri<\/th>\n\u00d6ng\u00f6r\u00fc Avantaj\u0131<\/th>\nLLY’ye \u00d6zg\u00fc Uygulama<\/th>\n<\/tr>\n<\/thead>\n
          Re\u00e7ete E\u011filimleri<\/td>\n\u00dc\u00e7 ayl\u0131k TRx toplamlar\u0131, y\u0131ll\u0131k b\u00fcy\u00fcme y\u00fczdeleri<\/td>\nHaftal\u0131k yeni marka re\u00e7eteleri, uzmanl\u0131k baz\u0131nda re\u00e7ete yazanlar\u0131n benimseme h\u0131z\u0131, 214 b\u00f6lge genelinde b\u00f6lgesel penetrasyon \u0131s\u0131 haritalar\u0131<\/td>\n%73 do\u011frulukla e\u011filim de\u011fi\u015fikliklerinin 3-6 hafta \u00f6nceki g\u00f6stergesi<\/td>\nMounjaro’nun h\u0131zlanan benimseme e\u011frisi IQVIA verilerinden 26 g\u00fcn \u00f6nce tespit edildi<\/td>\n<\/tr>\n
          Klinik Sonu\u00e7lar<\/td>\nYay\u0131nlanm\u0131\u015f deneme sonu\u00e7lar\u0131, resmi etiket g\u00fcncellemeleri<\/td>\n192.000’den fazla hasta kayd\u0131n\u0131n ger\u00e7ek d\u00fcnya kan\u0131t analizi, 46.000’den fazla sosyal medya hasta raporunun NLP analizi, yan etki k\u00fcmeleme algoritmas\u0131 izleme<\/td>\nOrtaya \u00e7\u0131kan etkinlik desenlerinin (%82 do\u011fru) veya g\u00fcvenlik sinyallerinin (%91 do\u011fru) erken uyar\u0131s\u0131<\/td>\nGLP-1 s\u0131n\u0131f\u0131 i\u00e7in ortaya \u00e7\u0131kan tiroid g\u00fcvenlik sinyali yay\u0131ndan 4 hafta \u00f6nce tespit edildi<\/td>\n<\/tr>\n
          Rekabet\u00e7i Konumland\u0131rma<\/td>\n\u00dc\u00e7 ayl\u0131k pazar pay\u0131 rakamlar\u0131, rakip lansman tarihleri<\/td>\n\u00dcr\u00fcnler aras\u0131nda g\u00fcnl\u00fck re\u00e7ete de\u011fi\u015ftirme desenleri, 38 \u00f6deme kapsam\u0131 algoritmas\u0131n\u0131n ML analizi, HCP anket verilerini kullanarak dinamik konumland\u0131rma alg\u0131 haritalamas\u0131<\/td>\nPazar verilerinden 3-5 hafta \u00f6nce %78 do\u011fru pay de\u011fi\u015fim tahmini<\/td>\nMounjaro’nun %12,3 pazar pay\u0131 kazan\u0131m\u0131 konsens\u00fcsten 37 g\u00fcn \u00f6nce tahmin edildi<\/td>\n<\/tr>\n
          \u00d6deme Ortam\u0131<\/td>\nOrtalama fiyat ger\u00e7ekle\u015ftirme, \u00fc\u00e7 ayl\u0131k br\u00fct-net tablolar\u0131<\/td>\nG\u00fcnl\u00fck form\u00fcl yerle\u015ftirme takibi, 27 plan genelinde \u00f6n yetkilendirme onay oran\u0131 izleme, co\u011frafyaya g\u00f6re hasta yard\u0131m program\u0131 kullan\u0131m\u0131<\/td>\n\u015eirket a\u00e7\u0131klamas\u0131ndan 5-7 hafta \u00f6nce %83 do\u011fru geri \u00f6deme zorluklar\u0131 tahmini<\/td>\nResmi duyurudan 18 g\u00fcn \u00f6nce Mounjaro kapsam\u0131n\u0131n iyile\u015fti\u011fi tespit edildi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
          \n

          Bu veri odakl\u0131 yakla\u015f\u0131mlar, Lilly’nin GLP-1 diyabet ve obezite franchise’lar\u0131n\u0131 de\u011ferlendirmek i\u00e7in ola\u011fan\u00fcst\u00fc de\u011fer sunar, burada erken re\u00e7ete e\u011filimleri pazar kabul\u00fc ve rekabet dinamikleri hakk\u0131nda kritik sinyaller sa\u011flar. Pocket Option’\u0131n re\u00e7ete e\u011filim analizi kullanan yat\u0131r\u0131mc\u0131lar, Mounjaro’nun h\u0131zlanan benimseme e\u011frisini konsens\u00fcs tahminleri bu e\u011frili\u011fi i\u00e7ermeden 31 g\u00fcn \u00f6nce belirledi ve bu da hisse senedi $423’e ula\u015ft\u0131\u011f\u0131nda $351’de giri\u015f f\u0131rsatlar\u0131 yaratt\u0131.<\/p>\n<\/div>\n

          \n
            \n
          • 46.700’den fazla hasta g\u00f6nderisinin sosyal medya duygu analizi, hasta memnuniyet seviyelerinin %83 do\u011fru tahminlerini sa\u011flar<\/li>\n
          • 31 milyon kapsanan ya\u015famdan sigorta talepleri verileri, \u015firket raporlamas\u0131ndan 27-41 g\u00fcn \u00f6nce ger\u00e7ek geri \u00f6deme desenlerini ortaya \u00e7\u0131kar\u0131r<\/li>\n
          • 14 uzmanl\u0131k dal\u0131nda doktor benimseme desenlerini g\u00f6steren 217.000 anonimle\u015ftirilmi\u015f hastadan elektronik sa\u011fl\u0131k kayd\u0131 verileri<\/li>\n
          • T\u0131bbi konferans duygu analizi, kilit g\u00f6r\u00fc\u015f lideri kabul\u00fcn\u00fc \u00f6l\u00e7erek sonraki re\u00e7ete e\u011filimleri i\u00e7in %79 \u00f6ng\u00f6r\u00fc do\u011frulu\u011fu sa\u011flar<\/li>\n<\/ul>\n<\/div>\n
            \n

            Pocket Option’\u0131n \u00f6zel veri analiti\u011fi panosu, bu farkl\u0131 veri ak\u0131\u015flar\u0131n\u0131, yat\u0131r\u0131mc\u0131lar\u0131n e\u011filim de\u011fi\u015fimlerini geni\u015f \u00e7apta tan\u0131nmadan \u00f6nce belirlemelerine yard\u0131mc\u0131 olan g\u00f6rselle\u015ftirme ara\u00e7lar\u0131na entegre eder. Sistemimiz, 2022-2023 y\u0131llar\u0131nda Lilly’nin anahtar re\u00e7ete e\u011filimlerindeki y\u00f6n de\u011fi\u015fikliklerini konsens\u00fcs analist revizyonlar\u0131nda g\u00f6r\u00fcnmeden 24-37 g\u00fcn \u00f6nce %76,8 do\u011frulukla tahmin etmi\u015ftir.<\/p>\n<\/div>\n

            \n

            IoT ve Ba\u011flant\u0131l\u0131 Cihazlar Yeni Gelir Ak\u0131\u015flar\u0131 Yarat\u0131yor<\/h2>\n<\/div>\n
            \n

            Nesnelerin \u0130nterneti (IoT) ve ba\u011flant\u0131l\u0131 t\u0131bbi cihazlar, lly hisse senedi tahmin modelleri i\u00e7in \u00f6nemli sonu\u00e7larla ortaya \u00e7\u0131kan bir s\u0131n\u0131r\u0131 temsil ediyor. Geleneksel ila\u00e7 gelir modelleri, neredeyse tamamen \u00fcr\u00fcn sat\u0131\u015flar\u0131na odaklanm\u0131\u015f olup, gelirin %87-92’si yaln\u0131zca ila\u00e7tan geliyordu. Ba\u011flant\u0131l\u0131 cihazlar\u0131n, izleme sistemlerinin ve dijital terap\u00f6tiklerin entegrasyonu, 2025 y\u0131l\u0131na kadar Lilly’nin gelirinin tahmini %11-14’\u00fcn\u00fc temsil edecek hibrit \u00fcr\u00fcn-hizmet modelleri yarat\u0131yor.<\/p>\n<\/div>\n

            \n

            Eli Lilly’nin ba\u011flant\u0131l\u0131 ins\u00fclin da\u011f\u0131t\u0131m sistemleri ve izleme platformlar\u0131na yapt\u0131\u011f\u0131 yat\u0131r\u0131mlar, teknoloji destekli ila\u00e7 i\u015f modellerine y\u00f6nelik bu kaymay\u0131 \u00f6rneklemektedir. \u015eirket, 2021’den bu yana ba\u011flant\u0131l\u0131 sa\u011fl\u0131k giri\u015fimlerine 387 milyon dolar yat\u0131r\u0131m yaparak \u00fc\u00e7 ana terap\u00f6tik alan\u0131 hedefliyor:<\/p>\n<\/div>\n

            \n
            \n\n\n\n\n\n\n\n\n
            \u0130\u015f Modeli Unsuru<\/th>\nGeleneksel \u0130la\u00e7 Yakla\u015f\u0131m\u0131<\/th>\nIoT Destekli Yakla\u015f\u0131m<\/th>\nDe\u011ferleme D\u00fc\u015f\u00fcncesi<\/th>\nLLY Ba\u011flant\u0131l\u0131 \u00c7\u00f6z\u00fcm<\/th>\n<\/tr>\n<\/thead>\n
            Gelir Yap\u0131s\u0131<\/td>\n%93 \u00fcr\u00fcn sat\u0131\u015f\u0131 ile tan\u0131mlanm\u0131\u015f patent u\u00e7urumlar\u0131, %7 hizmetler\/di\u011fer<\/td>\n%78 \u00fcr\u00fcn sat\u0131\u015f\u0131, %14 abonelik hizmetleri, %8 veri paraya \u00e7evirme (2025 hedefi)<\/td>\nDaha dengeli gelir ak\u0131\u015flar\u0131 ile daha y\u00fcksek hizmet marjlar\u0131 (%68 vs. %42)<\/td>\nBa\u011flant\u0131l\u0131 \u0130ns\u00fclin Kalemi + Tempo Ak\u0131ll\u0131 D\u00fc\u011fme (Q2 2022’de piyasaya s\u00fcr\u00fcld\u00fc)<\/td>\n<\/tr>\n
            M\u00fc\u015fteri \u0130li\u015fkisi<\/td>\nS\u0131n\u0131rl\u0131 do\u011frudan hasta etkile\u015fimi (y\u0131lda ortalama 1,7 temas noktas\u0131)<\/td>\nUygulamalar, izleme sistemleri ve destek platformlar\u0131 arac\u0131l\u0131\u011f\u0131yla y\u0131lda 37 dijital temas noktas\u0131<\/td>\nDaha y\u00fcksek ya\u015fam boyu de\u011fer ($41.700 vs. $29.400) ve azalan ge\u00e7i\u015f (%17 vs. %31)<\/td>\nMyPennPal Dijital Ekosistemi ile 784.000 aktif kullan\u0131c\u0131<\/td>\n<\/tr>\n
            Rekabet\u00e7i Farkl\u0131la\u015fma<\/td>\n\u00d6ncelikle kimyasal\/biyolojik \u00fcr\u00fcn farkl\u0131la\u015fmas\u0131<\/td>\n\u00dcr\u00fcnleri, cihazlar\u0131 ve dijital hizmetleri birle\u015ftiren entegre ekosistem ile %42 daha d\u00fc\u015f\u00fck terk oranlar\u0131<\/td>\nRekabet\u00e7i yer de\u011fi\u015ftirmeye kar\u015f\u0131 daha y\u00fcksek engeller<\/td>\nTempo Platformu Dexcom CGM ile entegrasyon (Q3 2023’te piyasaya s\u00fcr\u00fcld\u00fc)<\/td>\n<\/tr>\n
            Veri \u00dcretimi<\/td>\nKlinik denemeler ve periyodik pazarlama sonras\u0131 anketlerle s\u0131n\u0131rl\u0131<\/td>\nY\u0131lda hasta ba\u015f\u0131na ortalama 843 veri noktas\u0131 toplayan s\u00fcrekli ger\u00e7ek d\u00fcnya veri toplama<\/td>\n2025 y\u0131l\u0131na kadar tahmini 1,8 milyar dolar de\u011ferinde veri varl\u0131klar\u0131<\/td>\nLillyDiabetes Connect platformu (1,27 milyon hasta kay\u0131tl\u0131)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
            \n

            Hasta Uyumu Ekonomik Etkisi<\/h3>\n<\/div>\n
            \n

            Ba\u011flant\u0131l\u0131 cihazlar ve uyumu te\u015fvik eden teknolojiler, ila\u00e7lar\u0131n en kal\u0131c\u0131 zorluklar\u0131ndan birini ele al\u0131r: tedavi rejimlerine hasta uyumu. Geleneksel de\u011ferleme modelleri, \u00fcr\u00fcnler aras\u0131nda farkl\u0131l\u0131k g\u00f6stermeyen ila\u00e7 s\u0131n\u0131f\u0131na g\u00f6re standartla\u015ft\u0131r\u0131lm\u0131\u015f uyum oranlar\u0131n\u0131 varsayd\u0131. IoT destekli da\u011f\u0131t\u0131m ve izleme sistemleri, bu oranlar\u0131 %12-17 puan art\u0131rarak, 2025 y\u0131l\u0131na kadar tahmini 730 milyon dolar de\u011ferinde gelir etkileri ile g\u00f6sterilebilir \u015fekilde iyile\u015ftirmi\u015ftir.<\/p>\n<\/div>\n

            \n
            \n\n\n\n\n\n\n\n
            Terap\u00f6tik Alan<\/th>\nGeleneksel Uyum Oran\u0131<\/th>\nBa\u011flant\u0131l\u0131 \u00c7\u00f6z\u00fcm Uyum Oran\u0131<\/th>\nGelir Etkisi<\/th>\nSpesifik LLY \u00c7\u00f6z\u00fcm\u00fc<\/th>\n<\/tr>\n<\/thead>\n
            Diyabet (\u0130ns\u00fclin)<\/td>\n%67,4<\/td>\n%81,2 (+13,8 puan)<\/td>\nHasta ba\u015f\u0131na %17,2 gelir art\u0131\u015f\u0131 (y\u0131ll\u0131k $2.430)<\/td>\nTempo Ak\u0131ll\u0131 D\u00fc\u011fme + \u0130ns\u00fclin Yard\u0131mc\u0131 Uygulamas\u0131<\/td>\n<\/tr>\n
            Obezite (GLP-1 Agonistleri)<\/td>\n%56,3<\/td>\n%73,8 (+17,5 puan)<\/td>\nHasta ba\u015f\u0131na %20,7 gelir art\u0131\u015f\u0131 (y\u0131ll\u0131k $3.860)<\/td>\nMounjaro Connect Platformu ile 92.000 kay\u0131tl\u0131 hasta<\/td>\n<\/tr>\n
            \u0130mm\u00fcnoloji (Kendi Kendine Enjeksiyonlar)<\/td>\n%61,7<\/td>\n%74,2 (+12,5 puan)<\/td>\nHasta ba\u015f\u0131na %15,3 gelir art\u0131\u015f\u0131 (y\u0131ll\u0131k $5.210)<\/td>\nTaltz Yard\u0131mc\u0131 enjeksiyon izleme sistemi (Q1 2023’te piyasaya s\u00fcr\u00fcld\u00fc)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
            \n

            Lly hisse senedi fiyat tahmin modelleri geli\u015ftiren yat\u0131r\u0131mc\u0131lar i\u00e7in bu ba\u011flant\u0131l\u0131 sa\u011fl\u0131k giri\u015fimleri, ayr\u0131nt\u0131l\u0131 ROI analizi gerektirir. Uygulama maliyetleri, lansman a\u015famalar\u0131nda %0,3-0,5 marj bask\u0131s\u0131 yaratarak terap\u00f6tik alan ba\u015f\u0131na ortalama 41-57 milyon dolar aras\u0131nda de\u011fi\u015fir. Ancak, ba\u015far\u0131l\u0131 uygulama, tedavi kal\u0131c\u0131l\u0131k oranlar\u0131nda %14-23 art\u0131\u015flar sa\u011flayarak, enjeksiyon tedavileri i\u00e7in ortalama tedavi s\u00fcresini 8,7 aydan 11,4 aya kadar \u00f6nemli \u00f6l\u00e7\u00fcde uzat\u0131r. Bu uzat\u0131lm\u0131\u015f gelir s\u00fcresini yakalamak i\u00e7in de\u011ferleme modellerinizi ayarl\u0131yor musunuz?<\/p>\n<\/div>\n

            \n

            Pazar, bu teknolojik entegrasyonlar\u0131 tarihsel olarak yaln\u0131zca uygulama maliyetlerine odaklanarak ve ya\u015fam boyu de\u011fer iyile\u015ftirmelerini ka\u00e7\u0131rarak d\u00fc\u015f\u00fck de\u011ferlemi\u015ftir. Pocket Option’\u0131n \u00f6zel ba\u011flant\u0131l\u0131 sa\u011fl\u0131k de\u011ferleme hesaplay\u0131c\u0131s\u0131, yat\u0131r\u0131mc\u0131lar\u0131n hem k\u0131sa vadeli yat\u0131r\u0131mlar\u0131 hem de uzun vadeli ekonomik faydalar\u0131 \u00f6l\u00e7mesine yard\u0131mc\u0131 olarak hangi \u015firketlerin teknoloji yat\u0131r\u0131mlar\u0131n\u0131n muhtemelen \u00fcst\u00fcn getiri sa\u011flayaca\u011f\u0131n\u0131 belirler. Analizimiz, Lilly’nin IoT yat\u0131r\u0131mlar\u0131n\u0131n 8,4 ay i\u00e7inde pozitif ROI \u00fcretti\u011fini, ana rakipler i\u00e7in ise 14,7 ay s\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6stermektedir.<\/p>\n<\/div>\n

            \n

            Algoritmik Ticaretin LLY Hisse Senedi Fiyat Hareketleri \u00dczerindeki Etkisi<\/h2>\n<\/div>\n
            \n

            Do\u011frudan i\u015f etkilerinin \u00f6tesinde, teknolojik evrim, piyasalar\u0131n ila\u00e7 hisse senetlerini fiyatland\u0131rma \u015feklini k\u00f6kten de\u011fi\u015ftirdi. Algoritmik ticaretin y\u00fckseli\u015fi, piyasa mikro yap\u0131s\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrd\u00fc ve algoritmalar art\u0131k Lilly’nin g\u00fcnl\u00fck i\u015flem hacminin %76,4’\u00fcn\u00fc olu\u015fturuyor (2020’de %57,3’ten). Bu de\u011fi\u015fim, lly hisse senedi fiyat tahmin modellerini etkileyen belirgin fiyat ke\u015ffi ve oynakl\u0131k desenleri yarat\u0131r ve geleneksel analistler rutin olarak yanl\u0131\u015f yorumlar.<\/p>\n<\/div>\n

            \n

            Bu algoritmik sistemler, sofistike yat\u0131r\u0131mc\u0131lar\u0131n analizlerine dahil etmeleri gereken birka\u00e7 ay\u0131rt edici \u00f6zellik tan\u0131t\u0131r:<\/p>\n<\/div>\n

            \n
              \n
            • Klinik veri yay\u0131nlar\u0131 etraf\u0131nda olay odakl\u0131 oynakl\u0131k art\u0131\u015flar\u0131 (algoritma \u00f6ncesi d\u00f6nemde 2,2x’e kar\u015f\u0131 3,7x normal oynakl\u0131k)<\/li>\n
            • Ger\u00e7ek zamanl\u0131 ba\u015fl\u0131k analizine dayal\u0131 do\u011fal dil i\u015fleme tetiklemeli ticaret (haber bazl\u0131 hareketlerin %78’i 2,7 saniye i\u00e7inde ger\u00e7ekle\u015fir)<\/li>\n
            • Teknik sinyal amplifikasyonu, kendini g\u00fc\u00e7lendiren fiyat hareketleri yaratan desen tan\u0131ma algoritmalar\u0131 (trend g\u00fcnlerinin %41’i \u00f6ncelikle teknik algoritmalar taraf\u0131ndan y\u00f6nlendirilir)<\/li>\n
            • Se\u00e7enek odakl\u0131 fiyat dinamikleri, kataliz\u00f6r olaylar\u0131 s\u0131ras\u0131nda gamma s\u0131k\u0131\u015fmalar\u0131 yarat\u0131r (a\u015f\u0131r\u0131 hareketlerin %62’si >5% se\u00e7enek parmak izleri g\u00f6sterir)<\/li>\n<\/ul>\n<\/div>\n
              \n
              \n\n\n\n\n\n\n\n\n
              Piyasa Olay T\u00fcr\u00fc<\/th>\nGeleneksel Piyasa Tepkisi<\/th>\nAlgo Hakimiyetindeki Tepki<\/th>\nYat\u0131r\u0131mc\u0131 Sonucu<\/th>\nLLY’ye \u00d6zg\u00fc \u00d6rnek<\/th>\n<\/tr>\n<\/thead>\n
              Klinik Veri Yay\u0131n\u0131<\/td>\nAnalistler yorumlar\u0131n\u0131 yay\u0131nlad\u0131k\u00e7a 2-3 g\u00fcn i\u00e7inde kademeli fiyat ayarlamas\u0131<\/td>\nToplam hareketin %83’\u00fc, NLP ba\u015fl\u0131k taramas\u0131na dayal\u0131 olarak 47 dakika i\u00e7inde ger\u00e7ekle\u015fir, ard\u0131ndan 72 saat i\u00e7inde %31 tersine d\u00f6nme olas\u0131l\u0131\u011f\u0131<\/td>\n%15-20 pozisyon boyutland\u0131rma azaltmas\u0131 gerektiren daha y\u00fcksek k\u0131sa vadeli oynakl\u0131k<\/td>\nDonanemab Faz III sonu\u00e7lar\u0131: %15,8 kazanc\u0131n %87’si ilk 38 dakikada ger\u00e7ekle\u015fti<\/td>\n<\/tr>\n
              Kazan\u00e7 Raporlar\u0131<\/td>\nEPS vs. tahminler ve ileriye d\u00f6n\u00fck rehberlik \u00fczerine odaklanma<\/td>\nKazan\u00e7 \u00e7a\u011fr\u0131s\u0131 transkriptlerinin NLP’si, %73 \u00f6ng\u00f6r\u00fc de\u011feri ile 87 duygu ve dil desenini tan\u0131mlar<\/td>\n\u0130lan sonras\u0131 s\u00fcr\u00fcklenme desenleri 3-5 g\u00fcnden 1,5-2,7 g\u00fcne k\u0131sald\u0131<\/td>\nQ3 2023: Olumlu ba\u015fl\u0131k, olumsuz \u00e7a\u011fr\u0131 dili %4,7 tersine d\u00f6nme yaratt\u0131<\/td>\n<\/tr>\n
              D\u00fczenleyici Kararlar<\/td>\nOnay\/red \u00fczerine ikili sonu\u00e7 fiyatland\u0131rmas\u0131<\/td>\nTicari etkiler i\u00e7in onay mektuplar\u0131ndaki 31 dil unsurunu analiz eden sofistike desen tan\u0131ma<\/td>\nBelirli etiket k\u0131s\u0131tlamalar\u0131nda onay sonras\u0131 sat\u0131\u015flar\u0131n daha y\u00fcksek olas\u0131l\u0131\u011f\u0131 (%61 vs. %37)<\/td>\nTirzepatide onay\u0131: Algoritmalar belirli etiket s\u0131n\u0131rlamalar\u0131n\u0131 \u00e7\u00f6zd\u00fck\u00e7e ba\u015flang\u0131\u00e7ta %3,8 kazan\u00e7 -%2,3’e tersine d\u00f6nd\u00fc<\/td>\n<\/tr>\n
              Rakip Duyurular\u0131<\/td>\nAlg\u0131lanan rekabet\u00e7i etkiler \u00fczerine sekt\u00f6r genelinde ayarlamalar<\/td>\n\u0130statistiksel arbitraj algoritmalar\u0131, saniyeler i\u00e7inde 14 ilgili hisse senedi aras\u0131nda \u00e7ift ticaretleri y\u00fcr\u00fct\u00fcr<\/td>\nTemel etkiyle ilgisiz ge\u00e7ici fiyat bask\u0131s\u0131 (%72 geri d\u00f6n\u00fc\u015f 3 g\u00fcn i\u00e7inde)<\/td>\nNovo Nordisk GLP-1 verileri, 48 saat i\u00e7inde %5,3 toparlanma ile %6,8 LLY d\u00fc\u015f\u00fc\u015f\u00fcn\u00fc tetikledi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
              \n

              Bu teknolojik olarak y\u00f6nlendirilen piyasa dinamiklerini anlamak, lly hisse senedi tahmini 2025 projeksiyonlar\u0131na odaklanan yat\u0131r\u0131mc\u0131lar i\u00e7in hem zorluklar hem de f\u0131rsatlar yarat\u0131r. Artan oynakl\u0131k, rahats\u0131z edici fiyat dalgalanmalar\u0131 yarat\u0131rken (2020’den bu yana ortalama g\u00fcnl\u00fck aral\u0131k %46 geni\u015fledi), algoritmik ticaret, temel de\u011ferden ge\u00e7ici kopmalar yaratt\u0131\u011f\u0131nda taktik giri\u015f noktalar\u0131 da olu\u015fturur. Bu algoritmik a\u015f\u0131r\u0131l\u0131klardan yararlanmak i\u00e7in stratejiler geli\u015ftirdiniz mi?<\/p>\n<\/div>\n

              \n

              Pocket Option’\u0131n \u00f6zel teknik analiz paketi, “Algo-Sinyal” dedekt\u00f6r\u00fcm\u00fcz arac\u0131l\u0131\u011f\u0131yla bu algoritmik davran\u0131\u015f desenlerini i\u00e7erir ve yat\u0131r\u0131mc\u0131lar\u0131n teknik olarak y\u00f6nlendirilen fiyat hareketleri ile ger\u00e7ek temel de\u011fi\u015fiklikleri yans\u0131tanlar\u0131 ay\u0131rt etmelerine yard\u0131mc\u0131 olur. Sistemimiz, benzer desenler b\u00fcy\u00fck LLY olaylar\u0131ndan \u00f6nce ortaya \u00e7\u0131kt\u0131\u011f\u0131nda yat\u0131r\u0131mc\u0131lar\u0131n ilan sonras\u0131 fiyat davran\u0131\u015f\u0131n\u0131 %74 do\u011frulukla tahmin etmelerini sa\u011flayan ila\u00e7 kataliz\u00f6rleri etraf\u0131nda yedi tekrarlayan algoritmik imza tan\u0131mlam\u0131\u015ft\u0131r.<\/p>\n<\/div>\n

              \n

              Teknolojik Boyutlar\u0131 Kapsaml\u0131 LLY Hisse Analizine Entegre Etmek<\/h2>\n<\/div>\n
              \n

              Hem Eli Lilly’nin i\u015fini hem de piyasan\u0131n tepkisini yeniden \u015fekillendiren teknolojik g\u00fc\u00e7ler, birka\u00e7 geleneksel \u00e7er\u00e7evenin yakalad\u0131\u011f\u0131 \u00e7ok boyutlu bir analitik yakla\u015f\u0131m gerektirir. Sa\u011flam bir lly hisse tahmini geli\u015ftirmek, geleneksel finansal analizi, tek ba\u015f\u0131na geleneksel modellerden %37 daha fazla fiyat varyans\u0131n\u0131 a\u00e7\u0131klayan birka\u00e7 boyutta teknolojik evrimle entegre etmeyi gerektirir.<\/p>\n<\/div>\n

              \n

              Bu karma\u015f\u0131kl\u0131\u011f\u0131 ba\u015far\u0131yla y\u00f6neten yat\u0131r\u0131mc\u0131lar, genellikle teknolojik fakt\u00f6rleri geleneksel metriklerle birlikte sistematik olarak i\u00e7eren bu yap\u0131land\u0131r\u0131lm\u0131\u015f yakla\u015f\u0131m\u0131 izler:<\/p>\n<\/div>\n

              \n
              \n\n\n\n\n\n
              Analiz Boyutu<\/th>\nGeleneksel Odak<\/th>\nTeknoloji Destekli Odak<\/th>\nEntegrasyon Yakla\u015f\u0131m\u0131<\/th>\nLLY’ye \u00d6zg\u00fc Uygulama<\/th>\n<\/tr>\n<\/thead>\n
              Boru Hatt\u0131 De\u011ferlemesi<\/td>\nFaz bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 (%33\/%30\/%58), statik zirve sat\u0131\u015f tahminleri<\/td>\nML destekli bile\u015fik bazl\u0131 ba\u015far\u0131 tahminleri, dijital yard\u0131mc\u0131 etki benimseme e\u011frileri<\/td>\n27 farmakolojik parametreyi uygulayarak bile\u015fik ve endikasyona g\u00f6re olas\u0131l\u0131\u011f\u0131 ayarlay\u0131n<\/td>\nDonanemab: %64,7 Faz III ba\u015far\u0131 olas\u0131l\u0131\u011f\u0131, end\u00fcstri ortalamas\u0131 %58’e kar\u015f\u0131<\/\n<\/p>\n"},"faq":[{"question":"Yapay zeka, Eli Lilly'nin ila\u00e7 ke\u015fif s\u00fcrecini nas\u0131l etkiliyor ve bunun LLY hisse senedi tahmini i\u00e7in sonu\u00e7lar\u0131 nelerdir?","answer":"Eli Lilly, ila\u00e7 ke\u015ffinin birden fazla a\u015famas\u0131nda, \u00f6zellikle hedef do\u011frulama ve \u00f6nc\u00fc optimizasyonunda yapay zekay\u0131 uygulam\u0131\u015ft\u0131r. Kendi yapay zeka platformlar\u0131, aday belirleme s\u00fcrelerini 42 aydan 16,5 aya (y\u00fczde 60,7 azalma) d\u00fc\u015f\u00fcr\u00fcrken, molek\u00fcler kalite metriklerini y\u00fczde 37,2 oran\u0131nda iyile\u015ftirmi\u015ftir. 2025 y\u0131l\u0131 i\u00e7in lly hisse senedi tahmin modelleri geli\u015ftiren yat\u0131r\u0131mc\u0131lar i\u00e7in bu verimlilikler \u00fc\u00e7 \u00f6l\u00e7\u00fclebilir faydaya d\u00f6n\u00fc\u015fmektedir: 1) Ke\u015fiften IND'ye kadar olan s\u00fcrelerin k\u0131salmas\u0131, geliri yakla\u015f\u0131k 14 ay h\u0131zland\u0131rmaktad\u0131r, 2) Yapay zeka yard\u0131m\u0131yla tasarlanan bile\u015fikler i\u00e7in y\u00fczde 41,4'l\u00fck Faz I ba\u015far\u0131 oranlar\u0131, sekt\u00f6r standard\u0131 olan y\u00fczde 33'e k\u0131yasla daha iyidir ve 3) Y\u0131ll\u0131k 247 milyon dolarl\u0131k Ar-Ge verimlilik art\u0131\u015flar\u0131 do\u011frudan hisse ba\u015f\u0131na kazanca d\u00f6n\u00fc\u015fmektedir. En de\u011ferli yat\u0131r\u0131m uygulamalar\u0131, Lilly'nin n\u00f6rolojik hatt\u0131na odaklanmaktad\u0131r; burada yapay zeka ile tasarlanan molek\u00fcller, preklinik modellerde y\u00fczde 43 daha iyi kan-beyin bariyeri ge\u00e7i\u015fi ve y\u00fczde 29 daha az hedef d\u0131\u015f\u0131 etki g\u00f6stermi\u015ftir, bu da bu adaylar\u0131n risk ayarl\u0131 net bug\u00fcnk\u00fc de\u011ferini \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rmaktad\u0131r."},{"question":"Yat\u0131r\u0131mc\u0131lar, Lilly'nin tedarik zinciri y\u00f6netiminde blockchain uygulamas\u0131n\u0131n ba\u015far\u0131s\u0131n\u0131 de\u011ferlendirmek i\u00e7in hangi metrikleri izlemelidir?","answer":"Yat\u0131r\u0131mc\u0131lar, do\u011frudan de\u011ferlemeyi etkileyen d\u00f6rt kategori blockchain uygulama metri\u011fini takip etmelidir. \u0130lk olarak, envanter verimlili\u011fi \u00f6l\u00e7\u00fcmleri, envanterin elde tutulma s\u00fcresi (mevcut: 78 g\u00fcn, hedef: 52 g\u00fcn) ve i\u015fletme sermayesi da\u011f\u0131l\u0131m\u0131 (2025'e kadar potansiyel $147M iyile\u015fme). \u0130kinci olarak, \u00fcr\u00fcn b\u00fct\u00fcnl\u00fc\u011f\u00fc metrikleri, sahtecilik olaylar\u0131n\u0131n azalt\u0131lmas\u0131 (blockchain uygulanan pazarlarda %92 daha az soru\u015fturma) ve so\u011fuk zincir s\u0131cakl\u0131k sapma s\u0131kl\u0131\u011f\u0131 (blockchain ile izlenen sevkiyatlarda geleneksel izlemeye g\u00f6re %68 azalma). \u00dc\u00e7\u00fcnc\u00fc olarak, uyum verimlili\u011fi metrikleri, belge i\u015fleme s\u00fcresi (AB operasyonlar\u0131nda %43 azalma) ve d\u00fczenleyici denetim bulgular\u0131 (blockchain ile do\u011frulanm\u0131\u015f tesislerde %37 daha az g\u00f6zlem). D\u00f6rd\u00fcnc\u00fc olarak, finansal etki metrikleri, tedarik zinciri i\u015fletme gider oran\u0131 (2023'te %1.7 iyile\u015fme) ve br\u00fct marj etkisi (2025'e kadar %0.8-1.2 iyile\u015fme e\u011filiminde). En a\u00e7\u0131klay\u0131c\u0131 \u00f6nc\u00fc g\u00f6sterge, blockchain uygulama tamamlama y\u00fczdesidir; \u00fcr\u00fcn do\u011frulama i\u00e7in \u015fu anda %62, envanter y\u00f6netimi i\u00e7in %27, uyum belgeleri i\u00e7in %43 ve so\u011fuk zincir izleme i\u00e7in %74, her %10 uygulama ilerlemesi tarihsel olarak 3 \u00e7eyrek i\u00e7inde %0.2-0.3 marj iyile\u015fmesi ile ili\u015fkilendirilmi\u015ftir."},{"question":"Ba\u011flant\u0131l\u0131 cihazlar ve IoT entegrasyonu, Lilly'nin \u00fcr\u00fcnlerine hasta uyumunu nas\u0131l etkiliyor ve bunun gelir \u00fczerindeki etkisi nedir?","answer":"Lilly'nin ba\u011fl\u0131 sa\u011fl\u0131k giri\u015fimleri, \u00fc\u00e7 ana tedavi alan\u0131nda istatistiksel olarak anlaml\u0131 uyum iyile\u015ftirmeleri sa\u011flam\u0131\u015ft\u0131r. Tempo Smart Button ba\u011fl\u0131 ins\u00fclin kalemleri, 127.000 kay\u0131tl\u0131 diyabet hastas\u0131 aras\u0131nda tutarl\u0131 kullan\u0131m\u0131 %67,4'ten %81,2'ye \u00e7\u0131karm\u0131\u015ft\u0131r (%13,8 puanl\u0131k iyile\u015fme). Mounjaro Connect platformu, 92.000 kat\u0131l\u0131mc\u0131 aras\u0131nda GLP-1 tedavisi uyumunu %56,3'ten %73,8'e y\u00fckseltmi\u015ftir (%17,5 puanl\u0131k art\u0131\u015f). Taltz (ixekizumab) i\u00e7in enjeksiyon izleme sistemi, imm\u00fcnoloji rejimi uyumunu %61,7'den %74,2'ye \u00e7\u0131karm\u0131\u015ft\u0131r (%12,5 puanl\u0131k iyile\u015fme). Bu uyum iyile\u015ftirmeleri do\u011frudan gelire d\u00f6n\u00fc\u015fmektedir: ins\u00fclin \u00fcr\u00fcnleri, ba\u011fl\u0131 her hasta ba\u015f\u0131na y\u0131ll\u0131k ek gelir olarak $2,430 (17,2% art\u0131\u015f) \u00fcretirken, Mounjaro gibi haftal\u0131k GLP-1 resept\u00f6r agonistleri, uyumlu her hasta ba\u015f\u0131na y\u0131ll\u0131k $3,860 ek gelir sa\u011flamaktad\u0131r (20,7% art\u0131\u015f) ve ayl\u0131k imm\u00fcnoloji enjeksiyonlar\u0131, uyumlu her hasta ba\u015f\u0131na y\u0131ll\u0131k yakla\u015f\u0131k $5,210 eklemektedir (15,3% art\u0131\u015f). Mevcut kay\u0131t ve uyum iyile\u015ftirme oranlar\u0131na dayanarak, Lilly'nin ba\u011fl\u0131 sa\u011fl\u0131k giri\u015fimlerinin 2025 y\u0131l\u0131na kadar yakla\u015f\u0131k $730 milyon ek y\u0131ll\u0131k gelir \u00fcretmesi beklenmektedir ve yakla\u015f\u0131k $129 milyonluk uygulama maliyetleri ile ola\u011fan\u00fcst\u00fc bir 5.7x ROI sa\u011flamaktad\u0131r."},{"question":"Lilly'nin klinik deneme sonu\u00e7lar\u0131n\u0131 tahmin etmek i\u00e7in en etkili makine \u00f6\u011frenimi yakla\u015f\u0131mlar\u0131 nelerdir ve yat\u0131r\u0131mc\u0131lar bu i\u00e7g\u00f6r\u00fcleri nas\u0131l uygulayabilir?","answer":"Lilly'nin klinik sonu\u00e7lar\u0131n\u0131 tahmin etmek i\u00e7in en etkili ML yakla\u015f\u0131mlar\u0131, \u00fc\u00e7 tamamlay\u0131c\u0131 tekni\u011fi birle\u015ftirir. \u0130lk olarak, Lilly'nin adaylar\u0131n\u0131 15.000'den fazla benzer bile\u015fikle kar\u015f\u0131la\u015ft\u0131ran ve klinik ba\u015far\u0131 ile %87 korelasyon g\u00f6steren spesifik molek\u00fcler \u00f6zellikleri tan\u0131mlayan tekrarlayan sinir a\u011flar\u0131 kullanarak kimyasal yap\u0131 analizi. \u0130kincisi, 28.000 tarihsel denemeyi analiz ederek istatistiksel g\u00fc\u00e7lendirme, kat\u0131l\u0131m projeksiyonlar\u0131 ve son nokta se\u00e7imi uygunlu\u011funu de\u011ferlendiren deneme tasar\u0131m\u0131 de\u011ferlendirme algoritmalar\u0131, bu algoritmalar %76 do\u011frulukla Faz III sonu\u00e7lar\u0131n\u0131 do\u011fru tahmin etmi\u015ftir. \u00dc\u00e7\u00fcnc\u00fcs\u00fc, insan analistlerin genellikle g\u00f6zden ka\u00e7\u0131rd\u0131\u011f\u0131 erken faz verilerinde ince etkinlik sinyallerini tan\u0131mlayan biyomarker yan\u0131t deseni tan\u0131ma. Pratik uygulama i\u00e7in, yat\u0131r\u0131mc\u0131lar \u015funlar\u0131 yapmal\u0131d\u0131r: 1) Lilly'nin yay\u0131nlanm\u0131\u015f Faz II verilerini her endikasyon i\u00e7in ML taraf\u0131ndan belirlenen e\u015fiklerle kar\u015f\u0131la\u015ft\u0131r\u0131n (\u00f6rne\u011fin, Alzheimer adaylar\u0131 i\u00e7in minimum %21 amiloid azaltma), 2) Kat\u0131l\u0131m oranlar\u0131n\u0131 algoritma taraf\u0131ndan \u00fcretilen k\u0131yaslamalarla de\u011ferlendirin (Lilly'nin donanemab denemeleri \u00f6ng\u00f6r\u00fclenin 3.7 kat\u0131 daha h\u0131zl\u0131 kaydoldu, bu olumlu bir g\u00f6sterge), ve 3) Dijital biyomarker verilerini mevcut oldu\u011funda izleyin (Lilly'nin dijital bili\u015fsel de\u011ferlendirme puanlar\u0131, geleneksel \u00f6l\u00e7\u00fctlere g\u00f6re klinik sonu\u00e7larla %8.3 daha y\u00fcksek korelasyon g\u00f6sterdi). Pocket Option'\u0131n ML tabanl\u0131 deneme analiz\u00f6r\u00fc, bu teknikleri birle\u015ftirerek, 2021'den bu yana tahmin do\u011frulu\u011funda geleneksel faz tabanl\u0131 tahminleri %27 oran\u0131nda a\u015fan bile\u015fik bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 \u00fcretir."},{"question":"Yat\u0131r\u0131mc\u0131lar, Lilly hissesi \u00fczerindeki algoritmik ticaret etkilerini b\u00fcy\u00fck kataliz\u00f6rler etraf\u0131nda de\u011ferlendirme modellerini ayarlamak i\u00e7in nas\u0131l bir yol izlemelidir?","answer":"Algoritmik ticaret, LLY'nin fiyat davran\u0131\u015f\u0131n\u0131 \u00f6nemli kataliz\u00f6rler etraf\u0131nda temelden de\u011fi\u015ftirdi ve be\u015f spesifik de\u011ferleme modeli ayarlamas\u0131 gerektirdi. \u0130lk olarak, pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc artan volatiliteyi yans\u0131tmal\u0131d\u0131r; LLY art\u0131k kataliz\u00f6r olaylar\u0131 s\u0131ras\u0131nda %46 daha y\u00fcksek g\u00fcnl\u00fck fiyat aral\u0131klar\u0131 ve 3.7 kat normal volatilite (\u00f6nceki 2.2 kat ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda) ya\u015famaktad\u0131r. \u0130kinci olarak, kataliz\u00f6r zaman \u00e7izelgesi planlamas\u0131 s\u0131k\u0131\u015ft\u0131r\u0131lm\u0131\u015f tepki pencerelerini hesaba katmal\u0131d\u0131r; LLY'nin i\u015flem hacminin %76.4'\u00fc art\u0131k algoritmik olup, toplam kataliz\u00f6r hareketlerinin %83'\u00fc algoritma \u00f6ncesi d\u00f6nemdeki 2-3 g\u00fcn yerine 47 dakika i\u00e7inde ger\u00e7ekle\u015fmektedir. \u00dc\u00e7\u00fcnc\u00fc olarak, opsiyon pozisyonlama analizi \u00f6nem kazan\u0131r, \u00e7\u00fcnk\u00fc LLY'nin %5'i a\u015fan hareketlerinin %62'si y\u00f6nl\u00fc hareketleri art\u0131ran a\u00e7\u0131k\u00e7a opsiyon kaynakl\u0131 gamma etkileri g\u00f6stermektedir. D\u00f6rd\u00fcnc\u00fc olarak, teknik kurulum de\u011ferlendirmesi kritik \u00f6neme sahiptir \u00e7\u00fcnk\u00fc algoritma desen tan\u0131ma, trend g\u00fcnlerinin %41'ini olu\u015fturan kendini peki\u015ftiren fiyat hareketleri yarat\u0131r. Be\u015finci olarak, ba\u015fl\u0131k duyarl\u0131l\u0131\u011f\u0131 \u00f6l\u00e7\u00fcm\u00fc \u00f6nemli \u00f6l\u00e7\u00fcde \u00f6nem ta\u015f\u0131r, \u00e7\u00fcnk\u00fc haber b\u00fcltenlerinde \u00e7al\u0131\u015fan NLP ticaret algoritmalar\u0131, 72 saat i\u00e7inde %31 k\u0131smi geri d\u00f6n\u00fc\u015f olas\u0131l\u0131\u011f\u0131 ile keskin ba\u015flang\u0131\u00e7 hareketleri yarat\u0131r. En etkili strateji, temel kataliz\u00f6r de\u011ferlemesini teknik pozisyon fark\u0131ndal\u0131\u011f\u0131 ile birle\u015ftirir ve Pocket Option'\u0131n \"Algo-Signal\" dedekt\u00f6r\u00fcn\u00fc kullanarak, b\u00fcy\u00fck LLY haber olaylar\u0131n\u0131n ard\u0131ndan denge fiyat\u0131n\u0131n ortalama %7.3 alt\u0131nda giri\u015f f\u0131rsatlar\u0131 sa\u011flayan y\u00fcksek olas\u0131l\u0131kl\u0131 geri d\u00f6n\u00fc\u015f kurulumlar\u0131n\u0131 tan\u0131mlar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Yapay zeka, Eli Lilly'nin ila\u00e7 ke\u015fif s\u00fcrecini nas\u0131l etkiliyor ve bunun LLY hisse senedi tahmini i\u00e7in sonu\u00e7lar\u0131 nelerdir?","answer":"Eli Lilly, ila\u00e7 ke\u015ffinin birden fazla a\u015famas\u0131nda, \u00f6zellikle hedef do\u011frulama ve \u00f6nc\u00fc optimizasyonunda yapay zekay\u0131 uygulam\u0131\u015ft\u0131r. Kendi yapay zeka platformlar\u0131, aday belirleme s\u00fcrelerini 42 aydan 16,5 aya (y\u00fczde 60,7 azalma) d\u00fc\u015f\u00fcr\u00fcrken, molek\u00fcler kalite metriklerini y\u00fczde 37,2 oran\u0131nda iyile\u015ftirmi\u015ftir. 2025 y\u0131l\u0131 i\u00e7in lly hisse senedi tahmin modelleri geli\u015ftiren yat\u0131r\u0131mc\u0131lar i\u00e7in bu verimlilikler \u00fc\u00e7 \u00f6l\u00e7\u00fclebilir faydaya d\u00f6n\u00fc\u015fmektedir: 1) Ke\u015fiften IND'ye kadar olan s\u00fcrelerin k\u0131salmas\u0131, geliri yakla\u015f\u0131k 14 ay h\u0131zland\u0131rmaktad\u0131r, 2) Yapay zeka yard\u0131m\u0131yla tasarlanan bile\u015fikler i\u00e7in y\u00fczde 41,4'l\u00fck Faz I ba\u015far\u0131 oranlar\u0131, sekt\u00f6r standard\u0131 olan y\u00fczde 33'e k\u0131yasla daha iyidir ve 3) Y\u0131ll\u0131k 247 milyon dolarl\u0131k Ar-Ge verimlilik art\u0131\u015flar\u0131 do\u011frudan hisse ba\u015f\u0131na kazanca d\u00f6n\u00fc\u015fmektedir. En de\u011ferli yat\u0131r\u0131m uygulamalar\u0131, Lilly'nin n\u00f6rolojik hatt\u0131na odaklanmaktad\u0131r; burada yapay zeka ile tasarlanan molek\u00fcller, preklinik modellerde y\u00fczde 43 daha iyi kan-beyin bariyeri ge\u00e7i\u015fi ve y\u00fczde 29 daha az hedef d\u0131\u015f\u0131 etki g\u00f6stermi\u015ftir, bu da bu adaylar\u0131n risk ayarl\u0131 net bug\u00fcnk\u00fc de\u011ferini \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rmaktad\u0131r."},{"question":"Yat\u0131r\u0131mc\u0131lar, Lilly'nin tedarik zinciri y\u00f6netiminde blockchain uygulamas\u0131n\u0131n ba\u015far\u0131s\u0131n\u0131 de\u011ferlendirmek i\u00e7in hangi metrikleri izlemelidir?","answer":"Yat\u0131r\u0131mc\u0131lar, do\u011frudan de\u011ferlemeyi etkileyen d\u00f6rt kategori blockchain uygulama metri\u011fini takip etmelidir. \u0130lk olarak, envanter verimlili\u011fi \u00f6l\u00e7\u00fcmleri, envanterin elde tutulma s\u00fcresi (mevcut: 78 g\u00fcn, hedef: 52 g\u00fcn) ve i\u015fletme sermayesi da\u011f\u0131l\u0131m\u0131 (2025'e kadar potansiyel $147M iyile\u015fme). \u0130kinci olarak, \u00fcr\u00fcn b\u00fct\u00fcnl\u00fc\u011f\u00fc metrikleri, sahtecilik olaylar\u0131n\u0131n azalt\u0131lmas\u0131 (blockchain uygulanan pazarlarda %92 daha az soru\u015fturma) ve so\u011fuk zincir s\u0131cakl\u0131k sapma s\u0131kl\u0131\u011f\u0131 (blockchain ile izlenen sevkiyatlarda geleneksel izlemeye g\u00f6re %68 azalma). \u00dc\u00e7\u00fcnc\u00fc olarak, uyum verimlili\u011fi metrikleri, belge i\u015fleme s\u00fcresi (AB operasyonlar\u0131nda %43 azalma) ve d\u00fczenleyici denetim bulgular\u0131 (blockchain ile do\u011frulanm\u0131\u015f tesislerde %37 daha az g\u00f6zlem). D\u00f6rd\u00fcnc\u00fc olarak, finansal etki metrikleri, tedarik zinciri i\u015fletme gider oran\u0131 (2023'te %1.7 iyile\u015fme) ve br\u00fct marj etkisi (2025'e kadar %0.8-1.2 iyile\u015fme e\u011filiminde). En a\u00e7\u0131klay\u0131c\u0131 \u00f6nc\u00fc g\u00f6sterge, blockchain uygulama tamamlama y\u00fczdesidir; \u00fcr\u00fcn do\u011frulama i\u00e7in \u015fu anda %62, envanter y\u00f6netimi i\u00e7in %27, uyum belgeleri i\u00e7in %43 ve so\u011fuk zincir izleme i\u00e7in %74, her %10 uygulama ilerlemesi tarihsel olarak 3 \u00e7eyrek i\u00e7inde %0.2-0.3 marj iyile\u015fmesi ile ili\u015fkilendirilmi\u015ftir."},{"question":"Ba\u011flant\u0131l\u0131 cihazlar ve IoT entegrasyonu, Lilly'nin \u00fcr\u00fcnlerine hasta uyumunu nas\u0131l etkiliyor ve bunun gelir \u00fczerindeki etkisi nedir?","answer":"Lilly'nin ba\u011fl\u0131 sa\u011fl\u0131k giri\u015fimleri, \u00fc\u00e7 ana tedavi alan\u0131nda istatistiksel olarak anlaml\u0131 uyum iyile\u015ftirmeleri sa\u011flam\u0131\u015ft\u0131r. Tempo Smart Button ba\u011fl\u0131 ins\u00fclin kalemleri, 127.000 kay\u0131tl\u0131 diyabet hastas\u0131 aras\u0131nda tutarl\u0131 kullan\u0131m\u0131 %67,4'ten %81,2'ye \u00e7\u0131karm\u0131\u015ft\u0131r (%13,8 puanl\u0131k iyile\u015fme). Mounjaro Connect platformu, 92.000 kat\u0131l\u0131mc\u0131 aras\u0131nda GLP-1 tedavisi uyumunu %56,3'ten %73,8'e y\u00fckseltmi\u015ftir (%17,5 puanl\u0131k art\u0131\u015f). Taltz (ixekizumab) i\u00e7in enjeksiyon izleme sistemi, imm\u00fcnoloji rejimi uyumunu %61,7'den %74,2'ye \u00e7\u0131karm\u0131\u015ft\u0131r (%12,5 puanl\u0131k iyile\u015fme). Bu uyum iyile\u015ftirmeleri do\u011frudan gelire d\u00f6n\u00fc\u015fmektedir: ins\u00fclin \u00fcr\u00fcnleri, ba\u011fl\u0131 her hasta ba\u015f\u0131na y\u0131ll\u0131k ek gelir olarak $2,430 (17,2% art\u0131\u015f) \u00fcretirken, Mounjaro gibi haftal\u0131k GLP-1 resept\u00f6r agonistleri, uyumlu her hasta ba\u015f\u0131na y\u0131ll\u0131k $3,860 ek gelir sa\u011flamaktad\u0131r (20,7% art\u0131\u015f) ve ayl\u0131k imm\u00fcnoloji enjeksiyonlar\u0131, uyumlu her hasta ba\u015f\u0131na y\u0131ll\u0131k yakla\u015f\u0131k $5,210 eklemektedir (15,3% art\u0131\u015f). Mevcut kay\u0131t ve uyum iyile\u015ftirme oranlar\u0131na dayanarak, Lilly'nin ba\u011fl\u0131 sa\u011fl\u0131k giri\u015fimlerinin 2025 y\u0131l\u0131na kadar yakla\u015f\u0131k $730 milyon ek y\u0131ll\u0131k gelir \u00fcretmesi beklenmektedir ve yakla\u015f\u0131k $129 milyonluk uygulama maliyetleri ile ola\u011fan\u00fcst\u00fc bir 5.7x ROI sa\u011flamaktad\u0131r."},{"question":"Lilly'nin klinik deneme sonu\u00e7lar\u0131n\u0131 tahmin etmek i\u00e7in en etkili makine \u00f6\u011frenimi yakla\u015f\u0131mlar\u0131 nelerdir ve yat\u0131r\u0131mc\u0131lar bu i\u00e7g\u00f6r\u00fcleri nas\u0131l uygulayabilir?","answer":"Lilly'nin klinik sonu\u00e7lar\u0131n\u0131 tahmin etmek i\u00e7in en etkili ML yakla\u015f\u0131mlar\u0131, \u00fc\u00e7 tamamlay\u0131c\u0131 tekni\u011fi birle\u015ftirir. \u0130lk olarak, Lilly'nin adaylar\u0131n\u0131 15.000'den fazla benzer bile\u015fikle kar\u015f\u0131la\u015ft\u0131ran ve klinik ba\u015far\u0131 ile %87 korelasyon g\u00f6steren spesifik molek\u00fcler \u00f6zellikleri tan\u0131mlayan tekrarlayan sinir a\u011flar\u0131 kullanarak kimyasal yap\u0131 analizi. \u0130kincisi, 28.000 tarihsel denemeyi analiz ederek istatistiksel g\u00fc\u00e7lendirme, kat\u0131l\u0131m projeksiyonlar\u0131 ve son nokta se\u00e7imi uygunlu\u011funu de\u011ferlendiren deneme tasar\u0131m\u0131 de\u011ferlendirme algoritmalar\u0131, bu algoritmalar %76 do\u011frulukla Faz III sonu\u00e7lar\u0131n\u0131 do\u011fru tahmin etmi\u015ftir. \u00dc\u00e7\u00fcnc\u00fcs\u00fc, insan analistlerin genellikle g\u00f6zden ka\u00e7\u0131rd\u0131\u011f\u0131 erken faz verilerinde ince etkinlik sinyallerini tan\u0131mlayan biyomarker yan\u0131t deseni tan\u0131ma. Pratik uygulama i\u00e7in, yat\u0131r\u0131mc\u0131lar \u015funlar\u0131 yapmal\u0131d\u0131r: 1) Lilly'nin yay\u0131nlanm\u0131\u015f Faz II verilerini her endikasyon i\u00e7in ML taraf\u0131ndan belirlenen e\u015fiklerle kar\u015f\u0131la\u015ft\u0131r\u0131n (\u00f6rne\u011fin, Alzheimer adaylar\u0131 i\u00e7in minimum %21 amiloid azaltma), 2) Kat\u0131l\u0131m oranlar\u0131n\u0131 algoritma taraf\u0131ndan \u00fcretilen k\u0131yaslamalarla de\u011ferlendirin (Lilly'nin donanemab denemeleri \u00f6ng\u00f6r\u00fclenin 3.7 kat\u0131 daha h\u0131zl\u0131 kaydoldu, bu olumlu bir g\u00f6sterge), ve 3) Dijital biyomarker verilerini mevcut oldu\u011funda izleyin (Lilly'nin dijital bili\u015fsel de\u011ferlendirme puanlar\u0131, geleneksel \u00f6l\u00e7\u00fctlere g\u00f6re klinik sonu\u00e7larla %8.3 daha y\u00fcksek korelasyon g\u00f6sterdi). Pocket Option'\u0131n ML tabanl\u0131 deneme analiz\u00f6r\u00fc, bu teknikleri birle\u015ftirerek, 2021'den bu yana tahmin do\u011frulu\u011funda geleneksel faz tabanl\u0131 tahminleri %27 oran\u0131nda a\u015fan bile\u015fik bazl\u0131 ba\u015far\u0131 olas\u0131l\u0131klar\u0131 \u00fcretir."},{"question":"Yat\u0131r\u0131mc\u0131lar, Lilly hissesi \u00fczerindeki algoritmik ticaret etkilerini b\u00fcy\u00fck kataliz\u00f6rler etraf\u0131nda de\u011ferlendirme modellerini ayarlamak i\u00e7in nas\u0131l bir yol izlemelidir?","answer":"Algoritmik ticaret, LLY'nin fiyat davran\u0131\u015f\u0131n\u0131 \u00f6nemli kataliz\u00f6rler etraf\u0131nda temelden de\u011fi\u015ftirdi ve be\u015f spesifik de\u011ferleme modeli ayarlamas\u0131 gerektirdi. \u0130lk olarak, pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc artan volatiliteyi yans\u0131tmal\u0131d\u0131r; LLY art\u0131k kataliz\u00f6r olaylar\u0131 s\u0131ras\u0131nda %46 daha y\u00fcksek g\u00fcnl\u00fck fiyat aral\u0131klar\u0131 ve 3.7 kat normal volatilite (\u00f6nceki 2.2 kat ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda) ya\u015famaktad\u0131r. \u0130kinci olarak, kataliz\u00f6r zaman \u00e7izelgesi planlamas\u0131 s\u0131k\u0131\u015ft\u0131r\u0131lm\u0131\u015f tepki pencerelerini hesaba katmal\u0131d\u0131r; LLY'nin i\u015flem hacminin %76.4'\u00fc art\u0131k algoritmik olup, toplam kataliz\u00f6r hareketlerinin %83'\u00fc algoritma \u00f6ncesi d\u00f6nemdeki 2-3 g\u00fcn yerine 47 dakika i\u00e7inde ger\u00e7ekle\u015fmektedir. \u00dc\u00e7\u00fcnc\u00fc olarak, opsiyon pozisyonlama analizi \u00f6nem kazan\u0131r, \u00e7\u00fcnk\u00fc LLY'nin %5'i a\u015fan hareketlerinin %62'si y\u00f6nl\u00fc hareketleri art\u0131ran a\u00e7\u0131k\u00e7a opsiyon kaynakl\u0131 gamma etkileri g\u00f6stermektedir. D\u00f6rd\u00fcnc\u00fc olarak, teknik kurulum de\u011ferlendirmesi kritik \u00f6neme sahiptir \u00e7\u00fcnk\u00fc algoritma desen tan\u0131ma, trend g\u00fcnlerinin %41'ini olu\u015fturan kendini peki\u015ftiren fiyat hareketleri yarat\u0131r. Be\u015finci olarak, ba\u015fl\u0131k duyarl\u0131l\u0131\u011f\u0131 \u00f6l\u00e7\u00fcm\u00fc \u00f6nemli \u00f6l\u00e7\u00fcde \u00f6nem ta\u015f\u0131r, \u00e7\u00fcnk\u00fc haber b\u00fcltenlerinde \u00e7al\u0131\u015fan NLP ticaret algoritmalar\u0131, 72 saat i\u00e7inde %31 k\u0131smi geri d\u00f6n\u00fc\u015f olas\u0131l\u0131\u011f\u0131 ile keskin ba\u015flang\u0131\u00e7 hareketleri yarat\u0131r. En etkili strateji, temel kataliz\u00f6r de\u011ferlemesini teknik pozisyon fark\u0131ndal\u0131\u011f\u0131 ile birle\u015ftirir ve Pocket Option'\u0131n \"Algo-Signal\" dedekt\u00f6r\u00fcn\u00fc kullanarak, b\u00fcy\u00fck LLY haber olaylar\u0131n\u0131n ard\u0131ndan denge fiyat\u0131n\u0131n ortalama %7.3 alt\u0131nda giri\u015f f\u0131rsatlar\u0131 sa\u011flayan y\u00fcksek olas\u0131l\u0131kl\u0131 geri d\u00f6n\u00fc\u015f kurulumlar\u0131n\u0131 tan\u0131mlar."}]}},"yoast_head":"\nLLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T16:00:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?\",\"datePublished\":\"2025-07-22T16:00:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/\"},\"wordCount\":16,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp\",\"keywords\":[\"platform\",\"stock\",\"strategy\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/\",\"name\":\"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp\",\"datePublished\":\"2025-07-22T16:00:21+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/","og_locale":"tr_TR","og_type":"article","og_title":"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?","og_url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-22T16:00:21+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?","datePublished":"2025-07-22T16:00:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/"},"wordCount":16,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp","keywords":["platform","stock","strategy"],"articleSection":["Markets"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/","url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/","name":"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp","datePublished":"2025-07-22T16:00:21+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bitcoin-Taproot-vs-Native-Segwit-A-Comprehensive-Comparison-for-2025.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-forecast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"LLY Hisse Tahmini: Yapay Zeka ve Blockchain 30% Daha Do\u011fru Tahminler Nas\u0131l Sa\u011fl\u0131yor?"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":319848,"slug":"lly-stock-forecast","post_title":"D\u1ef1 b\u00e1o c\u1ed5 phi\u1ebfu LLY: C\u00e1ch AI v\u00e0 Blockchain th\u00fac \u0111\u1ea9y d\u1ef1 \u0111o\u00e1n ch\u00ednh x\u00e1c h\u01a1n 30%","href":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/lly-stock-forecast\/"},"pt_AA":{"locale":"pt_AA","id":319843,"slug":"lly-stock-forecast","post_title":"Previs\u00e3o de A\u00e7\u00f5es LLY: Como IA e Blockchain Impulsionam Previs\u00f5es 30% Mais Precisas","href":"https:\/\/pocketoption.com\/blog\/pt\/knowledge-base\/markets\/lly-stock-forecast\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/319846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=319846"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/319846\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/308120"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=319846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=319846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=319846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}